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Introduction
These guidelines for the treatment of patients with sexually transmitted diseases 
(STD) were established after consultation with a group of outside experts and staff of 
CDC.* These guidelines are based on available efficacy data, practical applicability, 
and cost. The recommendations should not be construed as rules, but rather as a 
source of clinical guidance within the United States. The guidelines focus on the 
treatment and counseling of individual patients and do not address other community 
services and interventions that may play roles in STD prevention. Clinical and 
laboratory diagnosis are briefly alluded to when appropriate in the context of therapy.
"Expert Consultants
King K. Holmes, MD, PhD (Co-Chair), Univ of Washington School of Medicine; P. Frederick 
Sparling, MD (Co-Chair), Univ of North Carolina School of Medicine; Jorge D. Blanco, MD, Texas 
Tech Univ Medical School; Gail Bolan, MD, San Francisco Dept of Public Health and UCSF 
School of Medicine; Virginia Caine, MD, Bellflower Clinic, Indianapolis; Margaret Hammer- 
schlag, MD, State Univ of New York Health Science Center at Brooklyn; Edward W. Hook III, MD, 
Johns Hopkins Univ School of Medicine and Baltimore City Health Department; Robert B. 
Jones, MD, PhD, Univ of Indiana School of Medicine; Franklyn N. Judson, MD, Denver Dept of 
Health and Departments of Medicine and Preventive Medicine, Univ of Colorado Health Science 
Center; William M. McCormack, MD, State Univ of New York Health Science Center at Brooklyn; 
Richard C. Reichman, MD, Univ of Rochester School of Medicine; Allan R. Ronald, MD, Univ of 
Manitoba Health Science Center (Winnipeg); A. Eugene Washington, MD, Stanford Univ School 
of Medicine; Richard J. Whitley, MD, University of Alabama School of Medicine; M. Lynn 
Yonekura, MD, UCLA School of Medicine.
Liaison Observers
Sandra Adamson Fryhofer, MD, American College of Physicians, Atlanta; H. Hunter 
Handsfield, MD, Seattle-King County Dept of Public Health/Univ of Washington/lnfectious 
Disease Society of America; William R. Bowie, MD, Univ of British Columbia; Canadian 
Laboratory Centre for Disease Control; Kenneth Noller, MD, Univ of Massachusetts and 
American College of Obstetricians and Gynecologists; Peter L. Perine, MD, Uniformed Svcs Univ 
of Health Sciences.
Staff, Centers for Disease Control
Willard Cates, Jr., MD, MPH, Director, Div of Sexually Transmitted Diseases, Center for 
Prevention Svcs; E. Russell Alexander, MD, Chief, Epidemiology Research Branch, Div of 
Sexually Transmitted Diseases, Center for Prevention Svcs.
STD Treatment Guidelines 1989 Project-Jonathan M. Zenilman, MD, Coordinator; Contribu­
tors: Robert C. Barnes, MD; Edward I. Galaid, MD, MPH; Yvonne T. Green, MSN; Stephen J. 
Kraus, MD; Joseph G. Lossick, DO, MS; John S. Moran, MD; Allyn K. Nakashima, MD; Thomas 
A. Peterman, MD, MSc; Herbert B. Peterson, MD; Robert T. Rolfs, Jr., MD; George P. 
Schmid, MD; Sandra K. Schwarcz, MD, MPH; Katherine M. Stone, MD; Kathleen Toomey, MD, 
MPH; William L. Whittington; Paul Zenker, MD, MPH. Editor: Martha S. Mayfield.
Staff: Sandra W. Bowden; Garrett K. Mallory.
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User's Guide
STD and their therapies have been categorized by etiologic agent, if possible. 
Some syndromes overlap; for example, urethritis may be caused by Neisseria 
gonorrhoeae or Chlamydia trachomatis. Table 1 correlates symptoms syndromes 
with etiologic organisms and directs the user to the appropriate section in this 
document.
TABLE 1. Correlation of symptoms/signs, organism/syndrome, and document sec­
tion.
Symptoms/signs Organism/syndrome Document section
Infections in Men
Urethritis Neisseria gonorrhoeae Gonorrhea
Chlamydia trachomatis Chlamydia
Herpes simplex virus (HSV) Herpes (primary)
Mycoplasma horn in is Nongonococcal urethritis (NGU)
Ureaplasma urealyticum NGU
Uncharacterized NGU
Epididymitis See specific section
Infections in Women
Cervicitis N. gonorrhoeae Gonorrhea
C. trachomatis Chlamydia
HSV Herpes
Mucopurulent cervicitis See specific section
Pelvic inflammatory disease See specific section
Vaginal infections Trichomonas vaginalis Trichomoniasis
Candida albicans Candida infections
Bacterial vaginosis (BV) See specific section









Human papillomavirus (HPV) Genital warts
Hepatitis B Hepatitis B
Cytomegalovirus (CMV) CMV
Genital ulcer disease T. pallidum Syphilis
Haemophilus ducreyi Chancroid
HSV Herpes
C. trachomatis Lymphogranuloma venereum (LGV)
Genital warts HPV Genital warts
Enteric infection See specific section
Proctitis (See also N. gonorrhoeae Gonorrhea
enteric infections) C. trachomatis Chlamydia
T. pallidum Syphilis
HSV Herpes
Other See Enteric Infection section
Ophthalmic disease N. gonorrhoeae Gonorrhea
(See specific section C. trachomatis Chlamydia
for general prevention)
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Abbreviations Used in This Publication
AIDS Acquired immunodeficiency syndrome
BV Bacterial vaginosis




DGI Disseminated gonococcal infection
DIS Disease Intervention Specialist(s)
ELISA Enzyme-linked immunosorbent assay
FTA-ABS Fluorescent treponemal antibody absorbed
HBIG Hepatitis B immune globulin
HBsAg Hepatitis B surface antigen
HIV Human immunodeficiency virus
HPV Human papillomavirus








PID Pelvic inflammatory disease
PPD Purified protein derivative
PPNG Penicillinase-producing N. gonorrhoeae
RPR Rapid plasma reagin
STD Sexually transmitted disease(s)
TCA Trichloroacetic acid
TRNG Tetracycline-resistant N. gonorrhoeae
VDRL Venereal Disease Research Laboratory
ZD V Zidovudine
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Clinician Guidelines And Public Health 
Considerations
Control of STD is based on four major concepts: 1) education of persons at risk on 
the modes of disease transmission and the means for reducing the risk of transmis­
sion; 2) detection of infection in asymptomatic persons and in persons who are 
symptomatic but unlikely to seek diagnostic and treatment services; 3) effective 
diagnosis and treatment of persons who are infected; and 4) evaluation, treatment, 
and counseling of sex partners of persons with an STD. Although this document deals 
largely with clinical aspects of STD control, the prevention of STD is based primarily 
on changing the sexual behaviors that put patients at risk.
Clinical Considerations
For persons requesting health services for evaluation of an STD, appropriate care 
consists of the following components (the temporal order of the interventions may 
vary, depending on the specific case and diagnosis):
History




Curative or palliative therapy 
Counseling and education 
Present episode of STD 
Prevention of future episodes 
Reporting of case when required 
Sex partner identification, notification, and evaluation 
Clinical follow-up when appropriate
Persons who are seeking health-care services for other reasons, but who are at risk 
for acquisition of STD*, should undergo the following as part of their routine health 
care:
•  STD risk assessment
•  Directed physical examination based on elicited symptoms
•  Screening for asymptomatic infections
In special situations, such as prenatal visits and legally induced abortions, 
screening for STD may have greater impact in preventing complications of STD. For 
specific recommendations in cases of sexual assault or child abuse, see "Sexual 
Assault and STD."
Specific guidelines for screening in each situation are beyond the scope of this 
document. However, whenever possible, the following laboratory screening tests for 
STD should be available:
*Persons at higher risk for STD include sexually active persons under 25 years of age, those who 
have had multiple sexual partners within the previous 6 months, and those with a history of STD. 
In addition, prostitutes and persons having sexual contact with prostitutes, users of illicit drugs, 
and inmates of detention centers have increased rates of STD and should be evaluated when 
seeking medical care.
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HIV antibody test (screening + confirmatory test)
Syphilis serology (nontreponemal test + treponemal confirmatory test)
Culture for N. gonorrhoeae
Culture or antigen test for C. trachomatis
Light microscopy for Gram's stain, wet mounts of vaginal secretions 
Dark-field microscopy for Treponema pallidum
Diagnosis of an STD should be considered a "sentinel event" reflecting unpro­
tected sexual activity. Patients with one STD are at high risk for having others. 
Therefore, patients should be closely evaluated for other STD infections, including 
syphilis and human immunodeficiency virus (HIV) serology (if not performed within 
the previous 3 months), gonorrhea and chlamydial testing from appropriate anatomic 
sites, and physical examination. Women wishing to prevent unplanned pregnancy 
and who are not using contraception should be counseled about contraception 
services; ideally, contraceptives and pregnancy testing should be available at the 
same facility providing STD services. Annual Pap smear evaluation should also be 
available.
Primary Prevention
Clinics and practitioners who treat patients with STD should have resources 
available for educating patients about risk assessment and behavioral choices. 
Behavioral assessment is an integral part of the STD history, and patients should be 
counseled on methods to lower their risk of acquiring STD, including abstinence, 
careful selection of partners, use of condoms and spermicides, and periodic exami­
nation. Specific recommendations for behavioral assessment and counseling are 
beyond the scope of these guidelines.
Condoms and Spermicides
Condoms and spermicides should be available in any facility providing clinical STD 
services. Instruction in proper use should also be provided. Although condoms do not 
provide absolute protection from any infection, if properly used, they reduce the risk 
of infection. Recommendations for the proper use of condoms (Table 2) have been 
made by CDC and other public health organizations.
Special Populations
Pregnant Women
Intrauterine or perinatally transmitted STD can have fatal or severely debilitating 
effects on the fetus. Routine prenatal care should include an assessment for STD, 
which in most cases includes serologic screening for syphilis and hepatitis B, testing 
for chlamydia, and gonorrhea culture (see specific sections for management of 
clinical disease). Prenatal screening for HIV is indicated for all patients with risk 
factors for HIV or with a high-risk sexual partner; some authorities recommend HIV 
screening of all pregnant women.
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Practical management issues are discussed in the sections pertaining to specific 
diseases. Pregnant women and their sexual partners should be questioned about STD 
and counseled about possible neonatal infections. Pregnant women with primary 
genital herpes infection, hepatitis B, primary cytomegalovirus (CMV) infection, or 
Group B streptococcal infection may need to be referred to an expert for manage­
ment. In the absence of lesions or other evidence of active disease, tests for herpes 
simplex virus (HSV) and cesarean delivery are not routinely indicated for women 
with a history of recurrent genital herpes infection during pregnancy. Routine HPV 
screening is not recommended. For a fuller discussion of these issues, as well as for 
infections not transmitted sexually, refer to "Guidelines for Perinatal Care" (second 
edition, 1988), jointly written and published by the American Academy of Pediatrics 
and the American College of Obstetricians and Gynecologists.
Children
Management of STD in children requires close cooperation between the clinician, 
laboratory, and child-protection authorities. Investigations, when indicated, should be 
initiated promptly. Some diseases, such as gonorrhea, syphilis, and chlamydia, if 
acquired after the neonatal period, are almost 100% indicative of sexual contact; in 
other diseases, such as HPV infection and vaginitis, the association with sexual 
contact is not so clear (see "Sexual Assault and STD").
TABLE 2. Recommendations for use of condoms
1. Latex condoms should be used because they may offer greater protection against HIV and 
other viral STD than natural membrane condoms.
2. Condoms should be stored in a cool, dry place out of direct sunlight.
3. Condoms in damaged packages or those that show obvious signs of age (e.g., those that are 
brittle, sticky, or discolored) should not be used. They cannot be relied upon to prevent 
infection or pregnancy.
4. Condoms should be handled with care to prevent puncture.
5. The condom should be put on before any genital contact to prevent exposure to fluids that 
may contain infectious agents. Hold the tip of the condom and unroll it onto the erect penis, 
leaving space at the tip to collect semen, yet ensuring that no air is trapped in the tip of the 
condom.
6. Only water-based lubricants should be used. Petroleum- or oil-based lubricants (such as 
petroleum jelly, cooking oils, shortening, and lotions) should not be used because they 
weaken the latex and may cause breakage.
7. Use of condoms containing spermicides may provide some additional protection against 
STD. However, vaginal use of spermicides along with condoms is likely to provide still 
greater protection.
8. If a condom breaks, it should be replaced immediately. If ejaculation occurs after condom 
breakage, the immediate use of spermicide has been suggested. However, the protective 
value of postejaculation application of spermicide in reducing the risk of STD transmission 
is unknown.
9. After ejaculation, care should be taken so that the condom does not slip off the penis before 
withdrawal; the base of the condom should be held throughout withdrawal. The penis 
should be withdrawn while still erect.
10. Condoms should never be reused.
Adapted from MMWR 1988;37:133-7.
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Patients with Multiple Episodes of STD ("Repeaters")
These patients have a disproportionately high rate of STD and should be targeted 
for intensive counseling on methods to reduce risk. More research is needed into 
methods of behavior modification for these patients, including the role of outreach 
and support services. In many cases, periodic call-back for STD evaluation may be 
indicated.
STD Core Groups
Populations of core STD transmitters account for most STD morbidity. Although 
substantial regional variation occurs, in most urban areas the core groups consist 
largely of ethnic minority populations with low levels of education and socioeco­
nomic attainment. In many such environments, illicit drug use and prostitution are 
common. Core groups are often geographically limited, permitting definition of core 
geographic areas as well as populations. STD programs should evaluate the occur­
rence of STD in their jurisdictions to define core populations and core areas for 
targeted education, screening, clinical outreach, call-back reexamination programs, 
and other control measures.
Illicit Drug Users
STD appear to be increasingly linked to illicit drug use. Illicit drug users may be at 
higher risk for sexual behaviors that put them at risk for STD. In addition, illicit drug 
users account for an increasing proportion of HIV infections. Further research is 
needed into the behaviors associated with drug use and STD, particularly to facilitate 
behavioral and clinical interventions targeted at drug users. Outreach programs in the 
community and in cooperation with drug treatment programs should be considered.
Prison and Detention Populations
Residents of short-term correctional and detention facilities often have high 
prevalence rates of STD. Screening and treatment for infections that are highly 
prevalent in the community should be provided for all inmates. In many situations, 
screening and treatment in the prison population is central to effective STD control. 
In addition, for many patients, correctional health services may be the only opportu­
nity for interaction with health-care providers.
Patients with HIV Infection and STD
The management of patients with STD who are coinfected with HIV presents 
complex clinical and behavioral issues. Because of its effect on the immune system, 
HIV may alter the natural histories of many STD, as well as the effect of antimicrobial 
therapy. Close clinical follow-up is imperative. STD infection in patients with and 
without HIV is a sentinel event, often indicating continued unprotected sexual activity. 
Further patient counseling is indicated in these situations.
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STD Reporting and Confidentiality
Disease surveillance activities, which include the accurate identification and timely 
reporting of STD, form an integral part of successful disease control. Reporting 
assists local health authorities in identifying sexual contacts who may be infected (see 
next section). Reporting is also important for assessing morbidity trends.
Reporting may be provider- and/or laboratory-based. Cases should be reported in 
accordance with local statutory requirements and in as timely a manner as possible. 
Clinicians who are unsure of local reporting requirements are encouraged to seek 
advice through their local health departments or state STD programs.
STD reports are held in strictest confidence and in many jurisdictions are protected 
by statute from subpoena. Before any follow-up of a positive STD test is conducted by 
STD program representatives, these personnel consult with the provider to verify the 
diagnosis and treatment. Most local health departments offer STD partner notification 
and follow-up services for selected STD.
Management of Sex Partners and Partner 
Notification
Clinical guidelines for management of sex partners are included in each disease 
section.
Breaking the chain of transmission is crucial to STD control. Further transmission 
and reinfection are prevented by referral of sex partners for diagnosis and treatment. 
Patients should ensure that their sex partners, including those without symptoms, are 
referred for evaluation. Partners of patients with STD should be examined; treatment 
should not be provided for partners who are not examined, except in rare instances 
such as when the partner is at a site remote from medical care. Appropriate referral 
for sex partners should be provided if care will not or cannot be provided by the initial 
health-care provider. Disease Intervention Specialists (DIS), i.e., public health profes­
sionals trained in STD management, can assist patients and practitioners in this 
process through interviewing and confidential field outreach procedures. Local and 
state health departments offer DIS referral services. Physicians and other community 
health personnel are encouraged to use DIS services to ensure complete case 
management. Health department managers should allocate DIS resources based on 
local morbidity patterns, outbreak situations, and available resources.
Medical Resources
Health-care providers caring for STD patients should ensure that medical re­
sources for the following are available either on site or through referral:
•  Medical evaluation and treatment facilities for HIV-infected patients
•  Hospitalization facilities for patients with complicated STD infection, such as 
pelvic inflammatory disease (PID) and disseminated gonococcal infection (DGI)
•  Medical, pediatric, infectious disease, dermatologic, and gynecological/ 
obstetrical referral services
•  Family planning services
•  Substance abuse treatment services
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AIDS and HIV Infection in The General 
STD Setting
The acquired immunodeficiency syndrome (AIDS) is a late manifestation of 
infection with human immunodeficiency virus (HIV). Most people infected with HIV 
remain asymptomatic for long periods. HIV infection is most often diagnosed by 
using HIV antibody tests. Detectable antibody usually develops within 3 months after 
infection. A confirmed positive antibody test means that a person is infected with HIV 
and is capable of transmitting the virus to others. Although a negative antibody test 
usually means a person is not infected, antibody tests cannot rule out infection from 
a recent exposure. If antibody testing is related to a specific exposure, the test should 
be repeated 3 and 6 months after the exposure.
Antibody testing for HIV begins with a screening test, usually an enzyme-linked 
immunosorbent assay (ELISA). If the screening test is positive, it is followed by a 
more specific confirmatory test, most commonly the Western blot assay. New 
antibody tests are being developed and licensed that are either easier to perform or 
more accurate. Positive results from screening tests must be confirmed before being 
considered definitive.
The time between infection with HIV and development of AIDS ranges from a few 
months to ^10 years. Most people who are infected with HIV will eventually have 
some symptoms related to that infection. In one cohort study, AIDS developed in 48% 
of a group of gay men ^10 years after infection; but additional AIDS cases are 
expected among those who have remained AIDS-free for >10 years.
Therapy with zidovudine (ZDV-previously known as azidothymidine) has been 
shown to benefit persons in the later stages of disease (AIDS or AIDS-related 
conditions along with a CD4 [T4] lymphocyte count less than 200/mm3). Serious side 
effects, usually anemias and cytopenias, have been common during therapy with 
ZDV; therefore, patients taking ZDV require careful follow-up in consultation with 
physicians who are familiar with ZDV therapy. Clinical trials are currently evaluating 
ZDV therapy for persons with asymptomatic HIV infection to see if it decreases the 
rate of progression to AIDS. Other trials are evaluating new drugs or combinations of 
drugs for persons with different stages of HIV infection, including asymptomatic 
infections. The complete therapeutic management of HIV infection is beyond the 
scope of this document.
Preventing the Sexual Transmission of HIV
The only way to prevent AIDS is to prevent the initial infection with HIV. Prevention 
of sexual transmission of HIV can be ensured in only two situations: 1) sexual 
abstinence or 2) choosing only sex partners who are not infected with HIV.
Many HIV-infected persons are asymptomatic and are unaware that they are 
infected. Therefore, without an antibody test, infected persons are difficult to identify. 
AIDS case surveillance and HIV seroprevalence studies allow estimation of risk for 
persons in different areas; however, these population estimates may have a limited 
impact on an individual's sexual decisions. Although knowledge of antibody status is 
desirable before a sexual relationship is initiated, this information may not be
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available. Therefore, individuals should be counseled that when they initiate a sexual 
relationship they should use sexual practices that reduce the risk of HIV transmission.
Sexual practices may influence the likelihood of HIV transmission during sexual 
contact with an infected partner. Women who practice anal intercourse with an 
infected partner are more likely to acquire infection than women who have only 
vaginal intercourse. The relative risk of transmission by oral-genital contact is 
probably somewhat lower than the risk of transmission by vaginal intercourse. Other 
STD or local trauma that breaks down the mucosal barrier to infection would be 
expected to increase the risk of HIV transmission. Condoms supplement natural 
barriers to infection and therefore reduce the risk of HIV transmission (see "Clinician 
Guidelines and Public Health Considerations").
When to Test for HIV
Voluntary, confidential, HIV antibody testing should be done routinely when the 
results may contribute either to the medical management of the person being 
tested or to the prevention of further transmission.
Testing is important for persons with symptoms of HIV-related illnesses or with 
diseases such as syphilis, chancroid, herpes, or tuberculosis, for which a positive test 
result might affect the recommended diagnostic evaluation, treatment, or follow-up. 
HIV counseling and testing for persons with STD is a particularly important part of an 
HIV prevention program, because patients who have acquired an STD have demon­
strated their potential risk for acquiring HIV.
Because no vaccine or cure is available, HIV prevention requires changes in 
behavior by people at risk for transmitting or acquiring infection. Therefore, patient 
counseling must be an integral part of any HIV testing program in an STD clinic. 
Counseling should be done both before and after HIV testing.
Pretest Counseling
Pretest counseling should include assessment of the patient's risk for HIV 
infection and measures to reduce that risk.
Intravenous (IV) drug users should be advised to stop using drugs. If they do not 
stop, they should not share needles. If needle-sharing continues, injection equipment 
should be cleaned with bleach between uses. Sexually active persons who have 
multiple partners should be advised to consider sexual abstinence or to enter a 
mutually monogamous relationship with a partner who has also been tested for HIV. 
Condoms should be used consistently if either or both partners are infected or have 
other partners. Similarly, heterosexuals with STD other than HIV should be encour­
aged to bring their partners in for HIV testing and to use condoms if they are not in 
a mutually monogamous relationship with an uninfected partner.
Posttest Counseling and Evaluation
Persons who have negative HIV antibody tests should be told their test result by 
a person who understands the need to reduce unsafe sexual behaviors and can 
explain ways to modify sexual practices to reduce risks.
Vol. 38 / No. S-8 MMWR 3
Antibody tests cannot detect infections that occurred in the several weeks before 
the test (see above). Persons who have negative tests should understand that the 
negative test result does not signify protection from acquiring infection. They should 
be advised about the ways the virus is transmitted and how to avoid infection. Their 
partners' risks for HIV infection should be discussed, and partners at risk should be 
encouraged to be tested for HIV.
Persons who test positive for HIV antibody should be told their test result by a 
person who is able to discuss the medical, psychological, and social implications 
of HIV infection. Routes of HIV transmission and methods to prevent further 
transmission should be emphasized.
Risks to past sexual and needle-sharing partners of HIV antibody-positive patients 
should be discussed, and they should be instructed in how to notify their partners and 
to refer them for counseling and testing. If they are unable to notify their partners or 
they are not sure that their partners will seek counseling, physicians or health 
department personnel should assist, using confidential procedures, to ensure that the 
partners are notified. Infected women should be advised of the risk of perinatal 
transmission (see below), and methods of contraception should be discussed and 
provided. Additional follow-up, counseling, and support systems should be available 
to facilitate psychosocial adjustment and changes in behavior among HIV antibody­
positive persons.
Perinatal Infections
Infants born to women with HIV infection may also be infected with HIV; this risk 
is estimated to be 30%-40%. The mother in such a case may be asymptomatic and her 
HIV infection not recognized at delivery. Infected neonates are usually asymptomatic, 
and currently HIV infection cannot be readily or easily diagnosed at birth. (A positive 
antibody test may reflect passively transferred maternal antibodies, and the infant 
must be observed over time to determine if neonatal infection is present.) Infection 
may not become evident until the child is 12-18 months of age. All pregnant women 
with a history of STD should be offered HIV counseling and testing. Recognition of 
HIV infection in pregnancy permits health-care workers to inform patients about the 
risks of transmission to the infant and the risks of continuing pregnancy.
Asymptomatic HIV Infections
As more HIV-infected persons are identified, primary health-care providers will 
need to assume increased responsibility for these patients. Most internists, pediatri­
cians, family practitioners, and gynecologists should be qualified to provide initial 
evaluation of HIV-infected individuals and follow-up of those with uncomplicated HIV 
infection. These services should be available in all public health clinics.
Health-care professionals who identify HIV-positive patients should provide 
posttest counseling; medical evaluation (either on site or by referral)-including a 
physical examination, complete blood count, lymphocyte subset analysis, syphilis 
serology, and a purified protein derivative (PPD) skin test for tuberculosis. 
Psychosocial counseling resources should also be available.
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All clinics and providers should establish and maintain contacts with resources in 
their regions for persons concerned about HIV infection, and they should refer 
patients when necessary. Possible resources for referral include counseling services, 
support groups, social workers, physicians, and clinics.
Diseases Characterized by Genital Ulcers or 
Inguinal Lymphadenopathy
In the United States, most patients with genital ulcers have genital herpes, syphilis, 
or chancroid. Inguinal lymphadenopathy is common in these infections. More than 
one of these diseases may be present in a patient. Patients who have genital ulcers 
may be at increased risk for HIV infection.
Diagnosis based only on history and physical examination is often inaccurate. 
Thus, evaluation of most persons with genital ulcers should include one or more of 
the following:
•  Dark-field examination or direct immunofluorescence test for T. pallidum
•  Serologic test(s) for syphilis
•  Culture or antigen test for HSV
•  Culture for Haemophilus ducreyi
Chancroid
Because of recent spread of H. ducreyi, chancroid has become an important STD 
in the United States. Its importance is enhanced by the knowledge that outside the 
United States chancroid has been associated with increased infection rates for HIV. 
Chancroid must be considered in the differential diagnosis of any patient with a 
painful genital ulcer. Painful inguinal lymphadenopathy is present in about half of all 
chancroid cases.
Recommended Regimen
Erythromycin base 500 mg orally 4 times a day for 7 days,
or
Ceftriaxone 250 mg intramuscularly (IM) in a single dose.
Alternative Regimen
Trimethoprim/sulfamethoxazole 160/800 mg (one double-strength tablet) orally 
2 times a day for 7 days.
Comment: The susceptibility of H. ducreyi to this combination of antimicrobial 
agents varies throughout the world; clinical efficacy should be monitored, prefer­
ably in conjunction with monitoring of susceptibility patterns.
or
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Amoxicillin 500 mg plus clavulanic acid 125 mg orally 3 times a day for 7 days. 
Comment: Not evaluated in the United States.
or
Ciprofloxacin 500 mg orally 2 times a day for 3 days.
Comment: Although a regimen of 500 mg orally once was effective outside the 
United States, based on pharmacokinetics and susceptibility data, 2- or 3-day 
regimens of the same dose may be prudent, especially for patients coinfected with 
HIV. Quinolones, such as ciprofloxacin, are contraindicated during pregnancy and 
in children 16 years of age or younger.
Management of Sex Partners
Sex partners, within the 10 days preceding onset of symptoms in an infected 
patient, whether symptomatic or not, should be examined and treated with a 
recommended regimen.
Follow-Up
If treatment is successful, ulcers due to chancroid symptomatically improve within 
3 days and objectively improve (evidenced by resolution of lesions and clearing of 
exudate) within 7 days after institution of therapy. Clinical resolution of lymphadeno- 
pathy is slower than that of ulcers and may require needle aspiration (through 
healthy, adjacent skin), even during successful therapy. Patients should be observed 
until the ulcer is completely healed. Because of the epidemiologic association with 
syphilis, serological testing for syphilis should be considered within 3 months after 
therapy.
Treatment Failures
If no clinical improvement is evident by 7 days after therapy, the clinician should 
consider whether 1) antimicrobials were taken as prescribed, 2) the H. ducreyi 
causing infection is resistant to the prescribed antimicrobial, 3) the diagnosis is 
correct, 4) coinfection with another STD agent exists, or 5) the patient is also infected 
with HIV. Preliminary information indicates that patients coinfected with HIV do not 
respond to antimicrobial therapy as well as patients not infected with HIV, especially 
when single-dose treatment is used. Antimicrobial susceptibility testing should be 





Dark-field examinations and direct fluorescent antibody tests on lesions or tissue 
are the definitive methods for diagnosing early syphilis. Presumptive diagnosis is 
possible by using two types of serologic tests for syphilis: 1) treponemal (e.g., 
fluorescent treponemal antibody absorbed [FTA-ABS], microhemagglutination assay
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for antibody to T. pallidum [MHATP]) and 2) nontreponemal (e.g., Venereal Disease 
Research Laboratory [VDRL], rapid plasma reagin [RPR]). Neither test alone is 
sufficient for diagnosis. Treponemal antibody tests, once positive, usually remain so 
for life, regardless of treatment or disease activity. Treponemal antibody titers do not 
correlate with disease activity and should be reported as positive or negative. 
Nontreponemal antibody titers do tend to correlate with disease activity, usually 
rising with new infection and falling after treatment. Nontreponemal antibody test 
results should be reported quantitatively and titered out to a final end point rather 
than reported as greater than an arbitrary cutoff (e.g., >1:512). With regard to 
changes in nontreponemal test results, a fourfold change in titers is equivalent to a 
two-dilution change-e.g., from 1:16 to 1:4, or from 1:8 to 1:32.
For sequential serologic tests, the same test (e.g., VDRL or RPR) should be used, 
and it should be run by the same laboratory. The VDRL and RPR are equally valid, but 
RPR titers are often slightly higher than VDRL titers and therefore are not comparable.
Neurosyphilis cannot be accurately diagnosed from any single test. Cerebrospinal 
fluid (CSF) tests should include cell count, protein, and VDRL (not RPR). The CSF 
leukocyte count is usually elevated (>5 WBC/mm3) when neurosyphilis is present and 
is a sensitive measure of the efficacy of therapy. VDRL is the standard test for CSF; 
when positive it is considered diagnostic of neurosyphilis. However, it may be 
negative when neurosyphilis is present and cannot be used to rule out neurosyphilis. 
Some experts also order an FTA-ABS; this may be less specific (more false positives) 
but is highly sensitive. The positive predictive value of the CSF-FTA-ABS is lower, but 
when negative, this test provides evidence against neurosyphilis.
Penicillin Therapy
Penicillin is the preferred drug for treating patients with syphilis. Penicillin is the 
only proven therapy that has been widely used for patients with neurosyphilis, 
congenital syphilis, or syphilis during pregnancy. For patients with penicillin allergy, 
skin testing-with desensitization, if necessary-is optimal. Sample guidelines for 
skin testing and desensitization are included (see Appendix to this section). However, 
the minor determinant mixture for penicillin is not currently available commercially.
Jarisch-Herxheimer Reaction
The Jarisch-Herxheimer reaction is an acute febrile reaction, often accompanied by 
headache, myalgia, and other symptoms, that may occur after any therapy for 
syphilis, and patients should be so warned. Jarisch-Herxheimer reactions are more 
common in patients with early syphilis. Antipyretics may be recommended, but no 
proven methods exist for preventing this reaction. Pregnant patients, in particular, 
should be warned that early labor may occur.
Persons Exposed to Syphilis (Epidemiologic Treatment)
Persons sexually exposed to a patient with early syphilis should be evaluated 
clinically and serologically. If the exposure occurred within the previous 90 days, the 
person may be infected yet seronegative and therefore should be presumptively
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treated. (It may be advisable to presumptively treat persons exposed more than 90 
days previously if serologic test results are not immediately available and follow-up 
is uncertain.) Patients who have other STD may also have been exposed to syphilis 
and should have a serologic test for syphilis. The dual therapy regimen currently 
recommended for gonorrhea (ceftriaxone and doxycycline) is probably effective 
against incubating syphilis. If a different, nonpenicillin antibiotic regimen is used to 
treat gonorrhea, the patient should have a repeat serologic test for syphilis in 
3 months.
Early Syphilis
Primary and Secondary Syphilis and Early Latent Syphilis of Less than 1 Year's 
Duration
Recommended Regimen
Benzathine penicillin G, 2.4 million units IM, in one dose. *•
Alternative Regimen for Penicillin-Allergic Patients (Nonpregnant)
Doxycycline, 100 mg orally 2 times a day for 2 weeks
or
Tetracycline, 500 mg orally 4 times a day for 2 weeks.
Doxycycline and tetracycline are equivalent therapies. There is less clinical 
experience with doxycycline, but compliance is better. In patients who cannot 
tolerate doxycycline or tetracycline, three options exist:
•  If follow-up or compliance cannot be ensured, the patient should have skin 
testing for penicillin allergy and be desensitized if necessary (see Appendix).
•  If compliance and follow-up are ensured, erythromycin, 500 mg orally 4 times a 
day for 2 weeks, can be used.
•  Patients who are allergic to penicillin may also be allergic to cephalosporins; 
therefore, caution must be used in treating a penicillin-allergic patient with a 
cephalosporin. However, preliminary data suggest that ceftriaxone, 250 mg IM 
once a day for 10 days, is curative-but careful follow-up is mandatory.
Follow-Up
Treatment failures can occur with any regimen. Patients should be reexamined 
clinically and serologically at 3 months and 6 months. If nontreponemal antibody 
titers have not declined fourfold by 3 months with primary or secondary syphilis, or 
by 6 months in early latent syphilis, or if signs or symptoms persist and reinfection 
has been ruled out, patients should have a CSF examination and be retreated 
appropriately.
HIV-infected patients should have more frequent follow-up, including serologic 
testing at 1, 2, 3, 6, 9, and 12 months. In addition to the above guidelines for 3 and 
6 months, any patient with a fourfold increase in titer at any time should have a CSF 
examination and be treated with the neurosyphilis regimen unless reinfection can be 
established as the cause of the increased titer.
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Lumbar Puncture in Early Syphilis
CSF abnormalities are common in adults with early syphilis. Despite the frequency 
of these CSF findings, very few patients develop neurosyphilis when the treatment 
regimens described above are used. Therefore, unless clinical signs and symptoms of 
neurologic involvement exist, such as optic, auditory, cranial nerve, or meningeal 
symptoms, lumbar puncture is not recommended for routine evaluation of early 
syphilis. This recommendation also applies to immunocompromised and HIV- 
infected patients, since no clear data currently show that these patients need 
increased therapy.
HIV Testing
All syphilis patients should be counseled concerning the risks of HIV and be 
encouraged to be tested for HIV.
Late Latent Syphilis of More Than 1 Year's Duration, Gummas, and 
Cardiovascular Syphilis
All patients should have a thorough clinical examination. Ideally, all patients with 
syphilis of more than 1 year's duration should have a CSF examination; however, 
performance of lumbar puncture can be individualized. In older asymptomatic 
individuals, the yield of lumbar puncture is likely to be low; however, CSF examina­
tion is clearly indicated in the following specific situations:
•  Neurologic signs or symptoms
•  Treatment failure
•  Serum nontreponemal antibody titer 2*1:32
•  Other evidence of active syphilis (aortitis, gumma, iritis)
•  Nonpenicillin therapy planned
•  Positive HIV antibody test
Note: If CSF examination is performed and reveals findings consistent with 
neurosyphilis, patients should be treated for neurosyphilis (see next section). 
Some experts also treat cardiovascular syphilis patients with a neurosyphilis 
regimen.
Recommended Regimen
Benzathine penicillin G, 7.2 million units total, administered as 3 doses of 
2.4 million units IM, given 1 week apart for 3 consecutive weeks.
Alternative Regimen for Penicillin-Allergic Patients (Nonpregnant)
Doxycycline, 100 mg orally 2 times a day for 4 weeks
or
Tetracycline, 500 mg orally 4 times a day for 4 weeks.
If patients are allergic to penicillin, alternate drugs should be used only after CSF 
examination has excluded neurosyphilis. Penicillin allergy is best determined by 
careful history taking, but skin testing may be used if the major and minor 
determinants are available (see Appendix).
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Follow-Up
Quantitative nontreponemal serologic tests should be repeated at 6 months and 
12 months. If titers increase fourfold, if an initially high titer (^ 1 :32) fails to decrease, 
or if the patient has signs or symptoms attributable to syphilis, the patient should be 
evaluated for neurosyphilis and retreated appropriately.
HIV Testing
All syphilis patients should be counseled concerning the risks of HIV and be 
encouraged to be tested for HIV antibody.
Neurosyphilis
Central nervous system disease may occur during any stage of syphilis. Clinical 
evidence of neurologic involvement (e.g., optic and auditory symptoms, cranial nerve 
palsies) warrants CSF examination.
Recommended Regimen
Aqueous crystalline penicillin G, 12-24 million units administered 2-4 million units 
every 4 hours IV, for 10-14 days.
Alternative Regimen (If Outpatient Compliance Can Be Ensured)
Procaine penicillin, 2-4 million units IM daily
and
Probenecid, 500 mg orally 4 times a day, both for 10-14 days.
Many authorities recommend addition of benzathine penicillin G, 2.4 million units 
IM weekly for three doses after completion of these neurosyphilis treatment 
regimens. No systematically collected data have evaluated therapeutic alternatives 
to penicillin. Patients who cannot tolerate penicillin should be skin tested and 
desensitized, if necessary, or managed in consultation with an expert.
Follow-Up
If an initial CSF pleocytosis was present, CSF examination should be repeated 
every 6 months until the cell count is normal. If it has not decreased at 6 months, or 
is not normal by 2 years, retreatment should be strongly considered.
HIV Testing
All syphilis patients should be counseled concerning the risks of HIV and be 
encouraged to be tested for HIV antibody.
Syphilis in Pregnancy
Screening
Pregnant women should be screened early in pregnancy. Seropositive pregnant 
women should be considered infected unless treatment history and sequential 
serologic antibody titers are showing an appropriate response. In populations in
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which prenatal care utilization is not optimal, patients should be screened, and if 
necessary, treatment provided at the time pregnancy is detected. In areas of high 
syphilis prevalence, or in patients at high risk, screening should be repeated in the 
third trimester and again at delivery.
Treatment
Patients should be treated with the penicillin regimen appropriate for the woman's 
stage of syphilis. Tetracycline and doxycycline are contraindicated in pregnancy. 
Erythromycin should not be used because of the high risk of failure to cure infection 
in the fetus. Pregnant women with histories of penicillin allergy should first be 
carefully questioned regarding the validity of the history. If necessary, they should 
then be skin tested and either treated with penicillin or referred for desensitization 
(see Appendix). Women who are treated in the second half of pregnancy are at risk for 
premature labor and/or fetal distress if their treatment precipitates a Jarisch- 
Herxheimer reaction. They should be advised to seek medical attention following 
treatment if they notice any change in fetal movements or have any contractions. 
Stillbirth is a rare complication of treatment; however, since therapy is necessary to 
prevent further fetal damage, this concern should not delay treatment.
Follow-Up
Monthly follow-up is mandatory so that retreatment can be given if needed. The 
antibody response should be the same as for nonpregnant patients.
HIV Testing
All syphilis patients should be counseled concerning the risks of HIV and be 
encouraged to be tested for HIV antibody.
Congenital Syphilis
Who Should be Evaluated
Infants should be evaluated if they were born to seropositive (nontreponemal test 
confirmed by treponemal test) women who:
•  Have untreated syphilis; or
•  Were treated for syphilis less than 1 month before delivery; or
•  Were treated for syphilis during pregnancy with a non-penicillin regimen; or
•  Did not have the expected decrease in nontreponemal antibody titers after 
treatment for syphilis; or
•  Do not have a well-documented history of treatment for syphilis; or
•  Were treated but had insufficient serologic follow-up during pregnancy to assess 
disease activity.
An infant should not be released from the hospital until the serologic status of its 
mother is known.
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Evaluation of the Infant
The clinical and laboratory evaluation of infants born to women described above 
should include:
•  A thorough physical examination for evidence of congenital syphilis
•  Nontreponemal antibody titer
•  CSF analysis for cells, protein, and VDRL
•  Long bone x-rays
•  Other tests as clinically indicated (e.g., chest x-ray)
•  If possible, FTA-ABS on the purified 19S-lgM fraction of serum (e.g., separation 
by Isolab columns)
Therapy Decisions
Infants should be treated if they have:
•  Any evidence of active disease (physical examination or x-ray); or
•  A reactive CSF-VDRL; or
•  An abnormal CSF finding (white blood cell count >5/mm3 or protein >50 
mg/dl)* regardless of CSF serology; or
•  Quantitative nontreponemal serologic titers that are fourfold (or greater) higher 
than their mother's; or
•  Positive FTA-ABS-19S-lgM antibody, if performed.
Even if the evaluation is normal, infants should be treated if their mothers have 
untreated syphilis or evidence of relapse or reinfection after treatment. Infants, who 
meet the criteria listed in "Who Should be Evaluated" but are not fully evaluated, 
should be assumed to be infected, and treated.
Treatment
Treatment should consist of: 100,000-150,000 units/kg of aqueous crystalline 
penicillin G daily (administered as 50,000 units/kg IV every 8-12 hours) or 50,000 
units/kg of procaine penicillin daily (administered once IM) for 10-14 days. If more 
than 1 day of therapy is missed, the entire course should be restarted. All symptom­
atic neonates should also have an ophthalmologic examination.
Infants who meet the criteria listed in "Who Should be Evaluated" but who after 
evaluation do not meet the criteria listed in "Therapy Decisions," are at low risk for 
congenital syphilis. If their mothers were treated with erythromycin during preg­
nancy, or if close follow-up cannot be assured, they should be treated with benza­
thine penicillin G, 50,000 units/kg IM as a one-time dose.
Follow-Up
Seropositive untreated infants must be closely followed at 1, 2, 3, 6, and 12 months 
of age. In the absence of infection, nontreponemal antibody titers should be 
decreasing by 3 months of age and should have disappeared by 6 months of age. If
*ln the immediate newborn period, interpretation of these tests may be difficult; normal values 
vary with gestational age and are higher in preterm infants. Other causes of elevated values 
should also be considered. However, when an infant is being evaluated for congenital syphilis, 
the infant should be treated if test results cannot exclude infection.
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these titers are found to be stable or increasing, the child should be reevaluated and 
fully treated. Additionally, in the absence of infection, treponemal antibodies may be 
present up to 1 year. If they are present beyond 1 year, the infant should be treated 
for congenital syphilis.
Treated infants should also be observed to ensure decreasing nontreponemal 
antibody titers; these should have disappeared by 6 months of age. Treponemal tests 
should not be used, since they may remain positive despite effective therapy if the 
child was infected. Infants with documented CSF pleocytosis should be reexamined 
every 6 months or until the cell count is normal. If the cell count is still abnormal after 
2 years, or if a downward trend is not present at each examination, the infant should 
be retreated. The CSF-VDRL should also be checked at 6 months; if it is still reactive, 
the infant should be retreated.
Therapy of Older Infants and Children
After the newborn period, children discovered to have syphilis should have a CSF 
examination to rule out congenital syphilis. Any child who is thought to have 
congenital syphilis or who has neurologic involvement should be treated with 
200,000-300,000 units/kg/day of aqueous crystalline penicillin G (administered as 
50,000 units/kg every 4-6 hours) for 10-14 days. Older children with definite acquired 
syphilis and a normal neurologic examination may be treated with benzathine 
penicillin G# 50,000 units/kg IM, up to the adult dose of 2.4 million units. Children with 
a history of penicillin allergy should be skin tested and, if necessary, desensitized (see 
Appendix). Follow-up should be performed as described previously.
HIV Testing
In cases of congenital syphilis, the mother should be counseled concerning the 
risks of HIV and be encouraged to be tested for HIV; if her test is positive, the infant 
should be referred for follow-up.
Syphilis in HIV-Infected Patients
Diagnosis
•  All sexually active patients with syphilis should be encouraged to be counseled 
and tested for HIV because of the frequency of association of the two diseases 
and the implications for clinical assessment and management.
•  Neurosyphilis should be considered in the differential diagnosis of neurologic 
disease in HIV-infected persons.
•  When clinical findings suggest that syphilis is present but serologic tests are 
negative or confusing, alternative tests, such as biopsy of lesions, dark-field 
examination, and direct fluorescent antibody staining of lesion material, should 
be used.
•  In cases of congenital syphilis, the mother should be encouraged to be 
counseled and tested for HIV; if her test is positive, the infant should be referred 
for follow-up.
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Treatment and Follow-Up
•  Penicillin regimens should be used whenever possible for all stages of syphilis 
in HIV-infected patients. Skin testing to confirm penicillin allergy may be used if 
minor and major determinants are available (see Appendix). However, data on 
its use in HIV-infected individuals are inadequate. Patients may be desensitized 
and treated with penicillin.
•  No change in therapy for early syphilis for HIV-coinfected patients is recom­
mended. However, some authorities advise CSF examination and/or treatment 
with a regimen appropriate for neurosyphilis for all patients coinfected with 
syphilis and HIV, regardless of the clinical stage of syphilis. In all cases, careful 
follow-up is necessary to ensure adequacy of treatment.
•  HIV-infected patients treated for syphilis should be followed clinically and with 
quantitative nontreponemal serologic tests (VDRL, RPR) at 1, 2, 3, 6, 9, and 
12 months after treatment. Patients with early syphilis whose titers increase or 
fail to decrease (see section on "Follow-Up, Early Syphilis") fourfold within 
6 months should undergo CSF examination and be retreated. In such patients, 
CSF abnormalities could be due to HIV-related infection, neurosyphilis, or both. 
STD clinics and other providers of STD treatment should ensure adequate 
follow-up.
Appendix
Management of Patients with Histories of Penicillin Allergy
Currently, no proven alternative therapies to penicillin are available for treating 
patients with neurosyphilis, congenital syphilis, or syphilis in pregnancy. Therefore, 
skin testing-with desensitization, if indicated —is recommended for these patients.
Skin Testing
Skin testing is a rapid, safe, and accurate procedure (see below). It is also 
productive; 90% of patients with histories of "penicillin allergy" have negative skin 
tests and can be given penicillin safely. The other 10% with positive skin tests have an 
increased risk of being truly penicillin-allergic and should undergo desensitization. 
Clinics involved in STD management should be equipped and prepared to do skin 
testing or should establish referral mechanisms to have skin tests performed.
Skin testing is quick; four determinants, along with positive and negative controls, 
can be placed and read in an hour (Table 3). Skin testing is also safe, if properly 
performed. Patients who have had a severe, life-threatening reaction in the past year 
should be tested in a controlled environment, such as a hospital setting, and the 
determinant antigens diluted 100-fold. Other patients can be skin-tested safely in a 
physician-staffed clinic. Patients with a history of penicillin allergy but with no 
reaction to penicillin skin tests, who are not on antihistamines and who had a positive 
histamine control on skin testing (Table 3), should be given penicillin, 250 mg orally, 
and observed for one hour. Patients who tolerate this dose well may be treated with 
penicillin as needed.
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Desensitization
Patients who have a positive skin test to one of the penicillin determinants can be 
desensitized. This is a straightforward, relatively safe procedure. Although the 
procedure can be done orally or intravenously, oral desensitization is thought to be 
safer, simpler, and easier. Desensitization should be done in a hospital setting 
because serious IgE-mediated allergic reaction, although unlikely, can occur. Desen­
sitization can be completed in 4 hours, after which the first dose of penicillin is given 
(Table 4). STD programs should have a referral center where patients with positive 
skin tests can be desensitized. After desensitization, patients must be maintained on 
penicillin for the duration of therapy.
TABLE 3. Penicillin allergy skin testing (adapted from Beall*)____________________
Note: If there has been a severe generalized reaction to penicillin in the previous year, the 
antigens should be diluted 100-fold, and patients should be tested in a controlled environment. 
Both major and minor determinants should be available for the tests to be interpretable. The 
patient should not have taken antihistamines in the previous 48 hours.
Reagents
Major determinants:
Benzylpenicilloyl-polylysine (major, Pre-Pen [Taylor Pharmacal Co., Decatur, Illinois],
6 x 10"5M)




Positive control (histamine, 1 mg/mL)
Negative control (buffered saline solution)
Dilute the antigens 100-fold for preliminary testing if there has been an immediate generalized 
reaction within the past year.
Procedure
Epicutaneous (scratch or prick) test: apply one drop of material to volar forearm and pierce 
epidermis without drawing blood; observe for 20 minutes. If there is no wheal ^ 4  mm, proceed 
to intradermal test.
Intradermal test: inject 0.02 ml intradermally with a 27-gauge short-bevelled needle; observe 
for 20 minutes.
Interpretation
For the test to be interpretable, the negative (saline) control must elicit no reaction and the 
positive (histamine) control must elicit a positive reaction.
Positive test: a wheal >4 mm in mean diameter to any penicillin reagent; erythema must be 
present.
Negative test: the wheals at the site of the penicillin reagents are equivalent to the negative 
control.
Indeterminate: all other results.
♦Reprinted with permission from Beall GN, Penicillins, pp 205-9. In: Saxon A, moderator. 
Immediate hypersensitivity reactions to beta lactam antibiotics. Ann Intern Med 1987; 107: 
204-15.
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TABLE 4. Oral-desensitization protocol (from Wendel)
Penicillin V Suspension _____Amount_____  Cumulative
Dose* (units/ml) ml units dose (units)
1 1,000 0.1 100 100
2 1,000 0.2 200 300
3 1,000 0.4 400 700
4 1,000 0.8 800 1,500
5 1,000 1.6 1,600 3,100
6 1,000 3.2 3,200 6,300
7 1,000 6.4 6,400 12,700
8 10,000 1.2 12,000 24,700
9 10,000 2.4 24,000 48,700
10 10,000 4.8 48,000 96,700
11 80,000 1.0 80,000 176,700
12 80,000 2.0 160,000 336,700
13 80,000 4.0 320,000 656,700
14 80,000 8.0 640,000 1,296,700
Observation period: 30 minutes before parenteral administration of penicillin.
^Interval between doses, 15 minutes; elapsed time, 3 hours and 45 minutes; cumulative dose, 
1.3 million units.
^ h e  specific amount of drug was diluted in approximately 30 ml of water and then given orally. 
Adapted with permission from the New England Journal of Medicine 1985;312:1229-32.
Lymphogranuloma Venereum
Lymphogranuloma venereum (LGV) is caused by C. trachomatis (LGV serovars). 
Inguinal lymphadenopathy is the most common clinical manifestation. Diagnosis is 
often made clinically and may be confused with chancroid. LGV is not a common 
cause of inguinal lymphadenopathy in the United States.
Treatment: Genital, inguinal, or anorectal
Recommended Regimen
Doxycycline 100 mg orally 2 times a day for 21 days.
Alternative Regimen
Tetracycline 500 mg orally 4 times a day for 21 days
or
Erythromycin 500 mg orally 4 times a day for 21 days
or
Sulfisoxazole 500 mg orally 4 times a day for 21 days or equivalent sulfonamide 
course.
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Genital Herpes Simplex Virus Infections
Genital herpes is a viral disease that may be chronic and recurring and for which 
no known cure exists. Systemic acyclovir treatment provides partial control of the 
symptoms and signs of herpes episodes; it accelerates healing but does not eradicate 
the infection nor affect the subsequent risk, frequency, or severity of recurrences after 
the drug is discontinued. Topical therapy with acyclovir is substantially less effective 
than therapy with the oral drug.
First Clinical Episode of Genital Herpes
Recommended Regimen
Acyclovir 200 mg orally 5 times a day for 7-10 days or until clinical resolution 
occurs.
First Clinical Episode of Herpes Proctitis
Recommended Regimen
Acyclovir 400 mg orally 5 times a day for 10 days or until clinical resolution occurs.
Inpatient Therapy
For patients with severe disease or complications necessitating hospitalization. 
Recommended Regimen
Acyclovir 5 mg/kg body weight IV every 8 hours for 5-7 days or until clinical 
resolution occurs.
Recurrent Episodes
Most episodes of recurrent herpes do not benefit from therapy with acyclovir. In 
severe recurrent disease, some patients who start therapy at the beginning of the 
prodrome or within 2 days after onset of lesions may benefit from therapy, although 
this has not been proven.
Recommended Regimen
Acyclovir 200 mg orally 5 times a day for 5 days
or
Acyclovir 800 mg orally 2 times a day for 5 days.
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Daily Suppressive Therapy
Daily treatment reduces frequency of recurrences by at least 75% among patients 
with frequent (more than six per year) recurrences. Safety and efficacy have been 
clearly documented among persons receiving daily therapy for up to 3 years. 
Acyclovir-resistant strains of HSV have been isolated from persons receiving sup­
pressive therapy, but they have not been associated with treatment failure among 
immunocompetent patients. After 1 year of continuous daily suppressive therapy, 
acyclovir should be discontinued so that the patient's recurrence rate may be 
reassessed.
Recommended Regimen
Acyclovir 200 mg orally 2 to 5 times a day*
or
Acyclovir 400 mg orally 2 times a day.*
Genital Herpes among HIV-Infected Patients
The need for higher-than-standard doses of oral acyclovir among HIV-infected but 
immunocompetent patients has not been established. Immune status, not HIV 
infection alone, is the likely predictor of disease severity and response to therapy. 
Case reports strongly suggest that patients with clinical immunodeficiency have a 
more severe clinical course of anogenital herpes than do immunocompetent patients, 
and some health-care providers are using increased doses of acyclovir for patients 
with immunodeficiency. However, neither the need for nor the proper increased 
dosage of acyclovir has been conclusively established. Immunocompromised as well 
as immunocompetent hosts who fail initial therapy may benefit from an increased 
dosage of acyclovir. The indications for suppressive therapy among immunocompro­
mised patients, and the dose required, are controversial. Clinical benefits to the 
patient must be weighed against the potential for selecting HSV strains that are 
resistant to acyclovir. Patients whose therapy for a recurrence fails because of 
resistant strains of HSV should be managed in consultation with an expert.
Acyclovir for Treating Pregnant Patients
The safety of systemic acyclovir therapy among pregnant women has not been 
established. In the presence of life-threatening maternal HSV infection (e.g., dissem­
inated infection that includes encephalitis, pneumonitis, and/or hepatitis) acyclovir 
administered IV is probably of value. Among pregnant women without life- 
threatening disease, systemic acyclovir treatment should not be used for recurrent 
genital herpes episodes or as suppressive therapy to prevent reactivation near term.
Perinatal Infections
Most mothers of infants who acquire neonatal herpes lack histories of clinically 
evident genital herpes. The risk of transmission to the neonate from an infected 
mother is highest among women with primary herpes infection near the time of
*Dosage must be individualized for each patient.
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delivery, and it is low among women with recurrent herpes. The results of viral 
cultures during pregnancy do not predict viral shedding at the time of delivery; such 
cultures are not routinely indicated.
At the onset of labor, all women should be examined and carefully questioned 
about symptoms. Women without symptoms or signs of genital herpes infection or 
prodrome may have vaginal deliveries. For women who have a history of genital 
herpes or who have a sex partner with genital herpes, cultures of the birth canal at 
delivery may be helpful in decisions about neonatal management. Infants delivered 
through an infected birth canal (proven by culture or presumed by observation of 
lesions) should be cultured and observed carefully. Although data are limited 
concerning the use of acyclovir for asymptomatic infants, some experts presump­
tively treat infants who were exposed to HSV at delivery. Herpes cultures should be 
obtained from infants before therapy; positive cultures obtained 24-48 hours or more 
after birth indicate active viral infection.
Counseling and Management of Sex Partners
Patients with genital herpes should be told about the natural history of their 
disease, with emphasis on the potential for recurrent episodes. Patients should be 
advised to abstain from sexual activity while lesions are present. Sexual transmission 
of HSV has been documented during periods without recognized lesions. Suppres­
sive treatment with oral acyclovir reduces the frequency of recurrences but does not 
totally eliminate viral shedding. Genital herpes and other diseases causing genital 
ulcers have been associated with an increased risk of acquiring HIV infections; 
therefore, condoms should be used during all sexual exposures. If sex partners of 
patients with genital herpes have genital lesions, they may benefit from evaluation; 
however, evaluation of asymptomatic partners is of little value in preventing trans­
mission of HSV.
The risk of neonatal infection should be explained to all patients —male and 
female —with genital herpes. Women of child-bearing age with genital herpes should 
be advised to inform their clinicians of their history during any future pregnancy.
Infections of Epithelial Surfaces
Genital Warts
Exophytic genital and anal warts are caused by certain types (most frequently 
types 6 and 11) of HPV. Other types sometimes present in the anogenital region (most 
commonly types 16, 18, and 31) have been found to be strongly associated with 
genital dysplasia and carcinoma. For this reason, a biopsy is needed in all instances 
of atypical, pigmented, or persistent warts. All women with anogenital warts should 
have an annual Pap smear.
Some subclinical HPV infections may be detected by Pap smear and colposcopy. 
Application of acetic acid may also indicate otherwise subclinical lesions, but 
false-positive tests occur. Tests for the detection of HPV-DNA are now widely
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available. The clinical use of these tests in managing individual patients is not known. 
Therefore, therapeutic decisions should not be made on the basis of these HPV-DNA 
tests.
No therapy has been shown to eradicate HPV. HPV has been demonstrated in 
adjacent tissue after laser treatment of HPV-associated cervical intraepithelial neo­
plasia and after attempts to eliminate subclinical HPV by extensive laser vaporization 
of the anogenital area. The benefit of treating patients with subclinical HPV infection 
has not been demonstrated, and recurrence is common. The effect of genital wart 
treatment on HPV transmission and the natural history of HPV is unknown. Therefore, 
the goat of treatment is removal of exophytic warts and the amelioration of signs 
and symptoms, not the eradication of HPV.
Expensive therapies, toxic therapies, and procedures that result in scarring should 
be avoided. Sex partners should be examined for evidence of warts. Patients with 
anogenital warts should be made aware that they are contagious to uninfected sex 
partners. The use of condoms is recommended to help reduce transmission.
In most clinical situations, cryotherapy with liquid nitrogen or cryoprobe is the 
treatment of choice for external genital and perianal warts. Cryotherapy is nontoxic, 
does not require anesthesia, and —if used properly —does not result in scarring. 
Podophyllin, trichloroacetic acid (TCA), and electrodesiccation/electrocautery are 
alternative therapies. Treatment with interferon is not recommended because of its 
relatively low efficacy, high incidence of toxicity, and high cost.
The carbon dioxide laser and conventional surgery are useful in the management 
of extensive warts, particularly for patients who have not responded to cryotherapy; 
these alternatives are not appropriate for limited lesions. Like more cost-effective 
treatments, these therapies do not eliminate HPV and often are associated with the 
recurrence of clinical cases.
Pregnant Patients and Perinatal Infections
Cesarean delivery for prevention of transmission of HPV infection to the newborn 
is not indicated. In rare instances, however, cesarean delivery may be indicated for 
women with genital warts if the pelvic outlet is obstructed or if vaginal delivery would 
result in excessive bleeding.
Genital papillary lesions have a tendency to proliferate and to become friable 
during pregnancy. Many experts advocate removal of visible warts during pregnancy, 
although data on this subject are limited.
HPV can cause laryngeal papillomatosis in infants. The route of transmission 
(transplacental, birth canal, or postnatal) is unknown; therefore, the preventive value 
of cesarean delivery is unknown. The perinatal transmission rate is also unknown, 
although it must be very low, given the relatively high prevalence of genital warts and 
the rarity of laryngeal papillomas. Neither routine HPV screening tests nor cesarean 
delivery are indicated to prevent transmission of HPV infection to the newborn.




Cryotherapy with liquid nitrogen or cryoprobe.
Alternative Regimen
Podophyllin 10%-25% in compound tincture of benzoin. Limit the total volume of 
podophyllin solution applied to <0.5 ml per treatment session. Thoroughly wash 
off in 1-4 hours. Treat <10 cm2 per session. Repeat applications at weekly intervals. 
Mucosal warts are more likely to respond than highly keratinized warts on the 
penile shaft, buttocks, and pubic areas. Contraindicated in pregnancy. 
Trichloroacetic acid (80%-90%). Apply only to warts; powder with talc or sodium 
bicarbonate (baking soda) to remove unreacted acid. Repeat application at weekly 
intervals.
Electrodesiccation/electrocautery. Electrodesiccation is contraindicated in pa­
tients with cardiac pacemakers, or for lesions proximal to the anal verge. Extensive 
or refractory disease should be referred to an expert.
Cervical Warts
Recommended Regimen
For women with cervical warts, dysplasia must be excluded before treatment is 




Cryotherapy with liquid nitrogen. (The use of a cryoprobe in the vagina is not 
recommended because of the risk of vaginal perforation and fistula formation.)
Alternative Regimen
Trichloroacetic acid (80%-90%). Apply only to warts; powder with talc or sodium 
bicarbonate (baking soda) to remove unreacted acid. Repeat application at weekly 
intervals.
Podophyllin 10%-25% in compound tincture of benzoin. Treatment area must be 
dry before speculum is removed. Treat <2 cm2 per session. Repeat application at 
weekly intervals. Contraindicated in pregnancy. Extensive or refractory disease 
should be referred to an expert.
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Urethral Meatus Warts
Recommended Regimen
Cryotherapy with liquid nitrogen.
Alternative Regimen
Podophyllin 10%-25% in compound tincture of benzoin. Treatment area must be 
dry before contact with normal mucosa, and podophyllin must be washed off in 
1-2 hours. Contraindicated in pregnancy. Extensive or refractory disease should 
be referred to an expert.
Anal Warts
Recommended Regimen
Cryotherapy with liquid nitrogen. Extensive or refractory disease should be 






Cryotherapy with liquid nitrogen.
Alternative Regimen
Electrodesiccation/electrocautery.
Surgical removal. Extensive or refractory disease should be referred to an expert.
Gonococcal Infections
Treatment of gonococcal infections in the United States is influenced by the 
following trends: 1) the spread of infections due to antibiotic-resistant N. gonor- 
rhoeae, including penicillinase-producing N. gonorrhoeae (PPNG), tetracycline- 
resistant N. gonorrhoeae (TRNG), and strains with chromosomally mediated resis­
tance to multiple antibiotics; 2) the high frequency of chlamydial infections in persons 
with gonorrhea; 3) recognition of the serious complications of chlamydial and 
gonococcal infections; and 4) the absence of a fast, inexpensive, and highly accurate 
test for chlamydial infection.
All gonorrhea cases should be diagnosed or confirmed by culture to facilitate 
antimicrobial susceptibility testing. The susceptibility of N. gonorrhoeae to antibio­
tics is likely to change over time in any locality. Therefore, gonorrhea control 
programs should include a system of regular antibiotic sensitivity testing of a 
surveillance sample of N. gonorrhoeae isolates as well as all isolates associated with 
treatment failure.
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Because of the wide spectrum of antimicrobial therapies effective against 
N. gonorrhoeae, these guidelines are not intended to be a comprehensive list of all 
possible treatment regimens.
Treatment of Adults
Uncomplicated Urethral, Endocervical, or Rectal Infections
Single-dose efficacy is a major consideration in choosing an antibiotic regimen to 
treat persons infected with N. gonorrhoeae. Another important concern is coexisting 
chlamydial infection, documented in up to 45% of gonorrhea cases in some popula­
tions. Until universal testing for chlamydia with quick, inexpensive, and highly 
accurate tests becomes available, persons with gonorrhea should also be treated for 
presumptive chlamydial infections. Generally, patients with gonorrhea infections 
should be treated simultaneously with antibiotics effective against both C. tracho­
matis and N. gonorrhoeae. Simultaneous treatment may lessen the possibility of 
treatment failure due to antibiotic resistance.
Recommended Regimen
Ceftriaxone 250 mg IM once
plus
Doxycycline 100 mg orally 2 times a day for 7 days.
Some authorities prefer a dose of 125 mg ceftriaxone IM because it is less 
expensive and can be given in a volume of only 0.5 ml, which is more easily 
administered in the deltoid muscle. However, the 250-mg dose is recommended 
because it may delay the emergence of ceftriaxone-resistant strains. At this time, 
both doses appear highly effective for mucosal gonorrhea at all sites.
Alternative Regimens
For patients who cannot take ceftriaxone, the preferred alternative is Spectinomy- 
cin 2 g IM, in a single dose (followed by doxycycline).
Other alternatives, for which experience is less extensive, include ciprofloxacin* 
500 mg orally once; norfloxacin* 800 mg orally once; cefuroxime axetil 1 g orally 
once with probenecid 1 g; cefotaxime 1 g IM once; and ceftizoxime 500 mg IM 
once. All of these regimens are folio wed by doxycycline 100 mg orally, twice daily 
for 7 days. If infection was acquired from a source proven not to have penicillin- 
resistant gonorrhea, a penicillin such as amoxicillin 3 g orally with 1 g probenecid 
followed by doxycycline may be used for treatment.
Doxycycline or tetracycline alone is no longer considered adequate therapy for 
gonococcal infections but is added for treatment of coexisting chlamydial infec­
tions. Tetracycline may be substituted for doxycycline; however, compliance may 
be worse since tetracycline must be taken at a dose of 500 mg 4 times a day 
between meals, whereas doxycycline is taken at a dose of 100 mg 2 times a day 
without regard to meals. Moreover, at current prices, tetracycline costs only a little 
less than generic doxycycline.
*Quinolones, such as ciprofloxacin and norfloxacin, are contraindicated during pregnancy and 
in children 16 years of age or younger.
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For patients who cannot take a tetracycline (e.g., pregnant women), erythromycin 
may be substituted (erythromycin base or stearate at 500 mg orally 4 times a day 
for 7 days or erythromycin ethylsuccinate, 800 mg orally 4 times a day for 7 days). 
See "Chlamydial Infections" for further information on management of chlamydial 
infection.
Special Considerations
All patients with gonorrhea should have a serologic test for syphilis and should be 
offered confidential counseling and testing for HIV infection. Most patients with 
incubating syphilis (those who are seronegative and have no clinical signs of syphilis) 
may be cured by any of the regimens containing p-lactams (e.g., ceftriaxone) or 
tetracyclines.
Spectinomycin and the quinolones (ciprofloxacin, norfloxacin) have not been 
shown to be active against incubating syphilis. Patients treated with these drugs 
should have a serologic test for syphilis in 1 month.
Patients with gonorrhea and documented syphilis and gonorrhea patients who are 
sex partners of syphilis patients should be treated for syphilis (see "Syphilis") as well 
as for gonorrhea.
Some practitioners report that mixing 1% lidocaine (without epinephrine) with 
ceftriaxone reduces the discomfort associated with the injection (see package insert). 
No adverse reactions have been associated with use of lidocaine diluent.
Management of Sex Partners
Persons exposed to gonorrhea within the preceding 30 days should be examined, 
cultured, and treated presumptively.
Follow-Up
Treatment failure following combined ceftriaxone/doxycycline therapy is rare; 
therefore, a follow-up culture ("test-of-cure") is not essential. A more cost-effective 
strategy may be a reexamination with culture 1-2 months after treatment ("rescreen­
ing"); this strategy detects both treatment failures and reinfections. Patients should 
return for examination if symptoms persist after treatment. Because there is less 
long-term experience with drugs other than ceftriaxone, patients treated with regi­
mens other than ceftriaxone/doxycycline should have follow-up cultures obtained for 
4-7 days after completion of therapy.
Treatment Failures
Persistent symptoms after treatment should be evaluated by culture for 
N. gonorrhoeae, and any gonococcal isolate should be tested for antibiotic sensitivity. 
Symptoms of urethritis may also be caused by C. trachomatis and other organisms 
associated with nongonococcal urethritis (see "Nongonococcal Urethritis"). Addi­
tional treatment for patients with gonorrhea should be ceftriaxone, 250 mg, followed 
by doxycycline. Infections occurring after treatment with one of the recommended 
regimens are commonly due to reinfection rather than to treatment failure and 
indicate a need for improved sex-partner referral and patient education.
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Pharyngeal Gonococcal Infection
Patients with uncomplicated pharyngeal gonococcal infection should be treated 
with ceftriaxone 250 mg IM once. Patients who cannot be treated with ceftriaxone 
should be treated with ciprofloxacin 500 mg orally as a single dose. Since experience 
with this regimen is limited, such patients should be evaluated with repeat culture 
4-7 days after treatment.
Treatment of Gonococcal Infections in Pregnancy
Pregnant women should be cultured for N. gonorrhoeae (and tested for 
C. trachomatis and syphilis) at the first prenatal-care visit. For women at high risk of 
STD, a second culture for gonorrhea (as well as tests for chlamydia and syphilis) 
should be obtained late in the third trimester.
Recommended Regimen
Ceftriaxone 250 mg IM once
plus
Erythromycin base* 500 mg orally 4 times a day for 7 days.
Pregnant women allergic to (3-lactams should be treated with spectinomycin 2 g IM 
once (followed by erythromycin). Follow-up cervical and rectal cultures for 
N. gonorrhoeae should be obtained 4-7 days after treatment is completed. 
Ideally, pregnant women with gonorrhea should be treated for chlamydia on the 
basis of chlamydial diagnostic studies. If chlamydial diagnostic testing is not 
available, treatment for chlamydia should be given. Tetracyclines (including 
doxycycline) and the quinolones are contraindicated in pregnancy because of 
possibly adverse effects on the fetus. Treatments for pregnant patients with 
chlamydial infection, acute salpingitis, and disseminated gonorrhea in pregnancy 
are described in respective sections.
Disseminated Gonococcal Infection (DGI)
Hospitalization is recommended for initial therapy, especially for patients who 
cannot reliably comply with treatment, have uncertain diagnoses, or have purulent 
synovial effusions or other complications. Patients should be examined for clinical 
evidence of endocarditis or meningitis.
Recommended Regimens—DGI Inpatient
Ceftriaxone 1 g, IM or IV, every 24 hours
or
Ceftizoxime 1 g, IV, every 8 hours
or
Cefotaxime 1 g, IV, every 8 hours.
Patients who are allergic to (3-lactam drugs should be treated with spectinomycin 
2 g IM every 12 hours.
"Erythromycin stearate 500 mg or erythromycin ethylsuccinate 800 mg or equivalent may be 
substituted for erythromycin base.
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When the infecting organism is proven to be penicillin-sensitive, parenteral 
treatment may be switched to ampicillin 1 g every 6 hours (or equivalent). 
Patients treated for DGI should be tested for genital C. trachomatis infection. If 
chlamydial testing is not available, patients should be treated empirically for 
coexisting chlamydial infection.
Reliable patients with uncomplicated disease may be discharged 24-48 hours after 
all symptoms resolve and may complete the therapy (for a total of 1 week of 
antibiotic therapy) with an oral regimen of cefuroxime axetil 500 mg 2 times a day 
or amoxicillin 500 mg with clavulanic acid 3 times a day or, if not pregnant, 
ciprofloxacin 500 mg 2 times a day.
Meningitis and Endocarditis
Meningitis and endocarditis caused by N. gonorrhoeae require high-dose IV 
therapy with an agent effective against the strain causing the disease, such as 
ceftriaxone 1-2 g IV every 12 hours. Optimal duration of therapy is unknown, but most 
authorities treat patients with gonococcal meningitis for 10-14 days and with 
gonococcal endocarditis for at least 4 weeks. Patients with gonococcal nephritis, 
endocarditis or meningitis, or recurrent DGI should be evaluated for complement 
deficiencies. Treatment of complicated DGI should be undertaken in consultation with 
an expert.
Adult Gonococcal Ophthalmia
Adults and children over 20 kg with nonsepticemic gonococcal ophthalmia should 
be treated with ceftriaxone 1 g IM once. Irrigation of the eyes with saline or buffered 
ophthalmic solutions may be useful adjunctive therapy to eliminate discharge. All 
patients must have careful ophthalmologic assessment, including slit-lamp examina­
tion for ocular complications. Topical antibiotics alone are insufficient therapy and are 
unnecessary when appropriate systemic therapy is given. Simultaneous ophthalmic 
infection with C. trachomatis has been reported and should be considered for 
patients who do not respond promptly.
Gonococcal Infections of Infants and Children
Child abuse should be carefully considered and evaluated (see "Sexual Assault 
and Abuse of Children") for any child with documented gonorrhea.
Treatment of Infants Born to Mothers with Gonococcal Infection
Infants born to mothers with untreated gonorrhea are at high risk of infection (e.g., 
ophthalmia and DGI) and should be treated with a single injection of ceftriaxone 
(50 mg/kg IV or IM, not to exceed 125 mg). Ceftriaxone should be given cautiously to
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hyperbilirubinemic infants, especially premature infants. Topical prophylaxis for 
neonatal ophthalmia is not adequate treatment for documented infections of the eye 
or other sites.
Treatment of Infants with Gonococcal Infection
Infants with documented gonococcal infections at any site (e.g., eye) should be 
evaluated for DGI. This evaluation should include a careful physical examination, 
especially of the joints, as well as blood and CSF cultures. Infants with gonococcal 
ophthalmia or DGI should be treated for 7 days (10 to 14 days if meningitis is present) 
with one of the following regimens:
Recommended Regimen
Ceftriaxone 25-50 mg/kg/day IV or IM in a single daily dose
or
Cefotaxime 25 mg/kg IV or IM every 12 hours.
Alternative Regimen
Limited data suggest that uncomplicated gonococcal ophthalmia among infants 
may be cured with a single injection of ceftriaxone (50 mg/kg up to 125 mg). A few 
experts use this regimen for children who have no clinical or laboratory evidence 
of disseminated disease.
If the gonococcal isolate is proven to be susceptible to penicillin, crystalline 
penicillin G may be given. The dose is 100,000 units/kg/day given in 2 equal doses 
(4 equal doses per day for infants more than 1 week old). The dose should be 
increased to 150,000 units/kg/day for meningitis.
Infants with gonococcal ophthalmia should receive eye irrigations with buffered 
saline solutions until discharge has cleared. Topical antibiotic therapy alone is 
inadequate. Simultaneous infection with C. trachomatis has been reported and 
should be considered for patients who do not respond satisfactorily. Therefore, the 
mother and infant should be tested for chlamydial infection.
Gonococcal Infections of Children
Children who weigh ^45 kg should be treated with adult regimens. Children who 
weigh <45 kg who have uncomplicated vulvovaginitis, cervicitis, urethritis, pharyn­
gitis, or proctitis should be treated as follows:
Recommended Regimen
Ceftriaxone 125 mg IM once.
Patients who cannot tolerate ceftriaxone may be treated with:
Spectinomycin 40 mg/kg IM once.
Patients weighing <45 kg with bacteremia or arthritis should be treated with 
ceftriaxone 50 mg/kg (maximum 1 g) once daily for 7 days. For meningitis, the 
duration of treatment is increased to 10-14 days and the maximum dose is 2 g.
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Children ^8 years of age should also be given doxycycline 100 mg 2 times a day 
for 7 days. All patients should be evaluated for coinfection with syphilis and 
C. trachomatis. Follow-up cultures are necessary to ensure that treatment has been 
effective.
Prevention of Ophthalmia Neonatorum
Instillation of a prophylactic agent into the eyes of all newborn infants is 
recommended to prevent gonococcal ophthalmia neonatorum and is required by law 
in most states. Although all regimens listed below effectively prevent gonococcal eye 
disease, their efficacy in preventing chlamydial eye disease is not clear. Furthermore, 
they do not eliminate nasopharyngeal colonization with C. trachomatis. Treatment of 
gonococcal and chlamydial infections in pregnant women is the best method for 
preventing neonatal gonococcal and chlamydial disease.
Recommended Regimen
Erythromycin (0.5%) ophthalmic ointment, once
or
Tetracycline (1%) ophthalmic ointment, once
or
Silver nitrate (1%) aqueous solution, once.
One of these should be instilled into the eyes of every neonate as soon as possible 
after delivery, and definitely within 1 hour after birth. Single-use tubes or ampules 
are preferable to multiple-use tubes.
The efficacy of tetracycline and erythromycin in the prevention of TRNG and PPNG 
ophthalmia is unknown, although both are probably effective because of the high 
concentrations of drug in these preparations. Bacitracin is not recommended.
Chlamydial Infections
Culture and nonculture methods for diagnosis of C. trachomatis are now available. 
Appropriate use of these diagnostic tests is strongly encouraged, especially for 
screening asymptomatic high-risk women in whom infection would otherwise be 
undetected. However, in clinical settings where testing for chlamydia is not routine or 
available, treatment often is prescribed on the basis of clinical diagnosis or as 
cotreatment for gonorrhea (see "Gonococcal Infections"). In clinical settings, periodic 
surveys should be performed to determine local chlamydial prevalence in patients 
with gonorrhea. Priority groups for chlamydia testing, if resources are limited, are 
high-risk pregnant women, adolescents, and women with multiple sexual partners.
Results of chlamydial tests should be interpreted with care. The sensitivity of all 
currently available laboratory tests for C. trachomatis tests is substantially less than 
100%; thus, false-negative tests are possible. Although the specificity of nonculture
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tests has improved substantially, false-positive test results may still occur with 
nonculture tests. Persons with chlamydial infections may remain asymptomatic for 
extended periods of time.
Treatment of Uncomplicated Urethral, Endocervical, or Rectal 
C. trachomatis Infections
Recommended Regimen
Doxycycline 100 mg orally 2 times a day for 7 days
or
Tetracycline 500 mg orally 4 times a day for 7 days. ___________________
Alternative Regimen
Erythromycin base 500 mg orally 4 times a day or equivalent salt for 7 days
or
Erythromycin ethylsuccinate 800 mg orally 4 times a day for 7 days.
If erythromycin is not tolerated because of side effects, the following regimen may 
be effective:
Sulfisoxazole 500 mg orally 4 times a day for 10 days or equivalent.
Test of Cure
Because antimicrobial resistance of C. trachomatis to recommended regimens has 
not been observed, test-of-cure evaluation is not necessary when treatment has been 
completed.
Treatment of C. trachomatis in Pregnancy
Pregnant women should undergo diagnostic testing for C. trachomatis, N. gonor- 
rhoeae, and syphilis, if possible, at their first prenatal visit and, for women at high risk, 
during the third trimester. Risk factors for chlamydial disease during pregnancy 
include young age (<25 years), past history or presence of other STD, a new sex 
partner within the preceding 3 months, and multiple sex partners. Ideally, pregnant 
women with gonorrhea should be treated for chlamydia on the basis of diagnostic 
studies, but if chlamydial testing is not available, treatment should be given because 
of the high likelihood of coinfection.
Recommended Regimen
Erythromycin base 500 mg orally 4 times a day for 7 days.
If this regimen is not tolerated, the following regimens are recommended:
Alternative Regimen
Erythromycin base 250 mg orally 4 times a day for 14 days
or
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Erythromycin ethylsuccinate 800 mg orally 4 times a day for 7 days
or
Erythromycin ethylsuccinate 400 mg orally 4 times a day for 14 days.
Alternative if Erythromycin Cannot Be Tolerated
Amoxicillin 500 mg orally 3 times a day for 7 days (limited data exist concerning 
this regimen).
Erythromycin estolate is contraindicated during pregnancy, since drug-related 
hepatoxicity can result.
Sex Partners of Patients with C. trachomatis Infections
Sex partners of patients who have C. trachomatis infection should be tested and 
treated for C. trachomatis if their contact was within 30 days of onset of symptoms. If 
testing is not available, they should be treated with the appropriate antimicrobial 
regimen.
Bacterial STD Syndromes 
Nongonococcal Urethritis
Among men with urethral symptoms, nongonococcal urethritis (NGU) is diag­
nosed by Gram stain demonstrating abundant polymorphonuclear leukocytes with­
out intracellular gram-negative diplococci. C. trachomatis has been implicated as the 
cause of NGU in about 50% of cases. Other organisms that cause 10%-15% of cases 
include Ureaplasma urealyticum, T. vaginalis, and herpes simplex virus. The cause of 
other cases is unknown.
Recommended Regimen
Doxycycline 100 mg orally 2 times a day for 7 days
or
Tetracycline 500 mg orally 4 times a day for 7 days.
Alternative Regimen
Erythromycin base 500 mg orally 4 times a day or equivalent salt for 7 days
or
Erythromycin ethylsuccinate 800 mg orally 4 times a day for 7 days.
If high-dose erythromycin schedules are not tolerated, the following regimen is 
recommended:
Erythromycin ethylsuccinate 400 mg orally 4 times a day for 14 days
or
Erythromycin base 250 mg orally 4 times a day or equivalent salt for 14 days.
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Management of Sex Partners
Sex partners of men with NGU should be evaluated for STD and treated with an 
appropriate regimen based on the evaluation.
Recurrent NGU Unresponsive to Conventional Therapy
Recurrent NGU may be due to lack of compliance with an initial antibiotic regimen, 
to reinfection due to failure to treat sex partners, or to factors currently undefined. If 
noncompliance or reinfection cannot be ruled out, repeat doxycycline (100 mg orally 
2 times a day for 7 days) or tetracycline (500 mg orally 4 times a day for 7 days).
If compliance with the initial antimicrobial agent is likely, treat with one of the 
above listed regimens.
If objective signs of urethritis continue after adequate treatment, these patients 
should be evaluated for evidence of other causes of urethritis and referred to a 
specialist.
Mucopurulent Cervicitis
The presence of mucopurulent endocervical exudate often suggests mucopurulent 
cervicitis (MPC) due to chlamydial or gonococcal infection. Presumptive diagnosis of 
MPC is made by the finding of mucopurulent secretion from the endocervix, which 
may appear yellow when viewed on a white cotton-tipped swab (positive swab test). 
Patients with MPC should have Gram stain and culture for N. gonorrhoeae, test for 
C. trachomatis, and a wet mount examination for T. vaginalis.
Recommended Regimen
If N. gonorrhoeae is found on Gram stain or culture of endocervical or urethral 
discharge, treatment should be the same as that recommended for uncomplicated 
gonorrhea in adults, including cotreatment for chlamydial infection.
If N. gonorrhoeae is not found, treatment should be the same as that recom­
mended for chlamydial infection in adults.
Management of Sex Partners
Sex partners of women with MPC should be evaluated for STD and treated with an 
appropriate regimen based on the evaluation.
Epididymitis
Among sexually active heterosexual men <35 years of age, epididymitis is most 
likely caused by N. gonorrhoeae or C. trachomatis. Specimens should be obtained for 
a urethral smear for Gram stain and culture for N. gonorrhoeae and C. trachomatis 
and for a urine culture. Empiric therapy based on the clinical diagnosis is recom­
mended before culture results are available.
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Recommended Regimen 
Ceftriaxone 250 mg IM once
and
Doxycycline 100 mg orally 2 times a day for 10 days
or
Tetracycline 500 mg orally 4 times a day for 10 days.
Pelvic Inflammatory Disease
Treatment Guidelines
Pelvic inflammatory disease (PID) comprises a spectrum of inflammatory disorders 
of the upper genital tract in women. PID may include endometritis, salpingitis, 
tubo-ovarian abscess, and pelvic peritonitis. Sexually transmitted organisms, espe­
cially N. gonorrhoeae and C. trachomatis, are implicated in most cases; however, 
endogenous organisms, such as anaerobes, gram-negative rods, streptococci, and 
mycoplasmas, may also be etiologic agents of disease.
A confirmed diagnosis of salpingitis and more accurate bacteriologic diagnosis is 
made by laparoscopy. Since laparoscopy is not always available, the diagnosis of PID 
is often based on imprecise clinical findings and culture or antigen detection tests of 
specimens from the lower genital tract.
Guidelines for the treatment of patients with PID have been designed to provide 
flexibility in therapeutic choices. PID therapy regimens are designed to provide 
empiric, broad-spectrum coverage of likely etiologic pathogens. Antimicrobial cover­
age should include N. gonorrhoeae, C. trachomatis, gram-negatives, anaerobes, 
Group B streptococcus, and the genital mycoplasmas. Limited data demonstrate that 
effective treatment of the upper genital tract pyogenic process will decrease the 
incidence of long-term complications such as tubal infertility and ectopic pregnancy.
Ideally, as for all intra-abdominal infections, hospitalization is recommended 
whenever possible, and particularly when 1) the diagnosis is uncertain; 2) surgical 
emergencies such as appendicitis and ectopic pregnancy cannot be excluded; 3) a 
pelvic abscess is suspected; 4) the patient is pregnant; 5) the patient is an adolescent 
(the compliance of adolescent patients with therapy is unpredictable, and the 
long-term sequelae of PID may be particularly severe in this group); 6) severe illness 
precludes outpatient management; 7) the patient is unable to follow or tolerate an 
outpatient regimen; 8) the patient has failed to respond to outpatient therapy; or 
9) clinical follow-up within 72 hours of starting antibiotic treatment cannot be 
arranged. Many experts recommend that all patients with PID be hospitalized so that 
treatment with parenteral antibiotics can be initiated.
Selection of a treatment regimen must consider institutional availability, cost- 
control efforts, patient acceptance, and regional differences in antimicrobial suscep­
tibility.
These treatment regimens are recommendations only and the specific antibiotics 
named are examples. Treatments used for PID will continue to be broad spectrum and 
empiric until more definitive studies are performed.
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Inpatient treatment
One of the following:
Recommended Regimen A
Cefoxitin 2 g IV every 6 hours, or cefotetan* IV 2 g every 12 hours
plus
Doxycycline 100 mg every 12 hours orally or IV.______________________________
The above regimen is given for at least 48 hours after the patient clinically 
improves.
After discharge from hospital, continuation of:
Doxycycline 100 mg orally 2 times a day for a total of 10-14 days.
Recommended Regimen B
Clindamycin IV 900 mg every 8 hours
plus
Gentamicin loading dose IV or IM (2 mg/kg) followed by a maintenance dose 
(1.5 mg/kg) every 8 !' jurs.
The above regimen is given for at least 48 hours after the patient improves. After 
discharge from hospital, continuation of:
Doxycycline 100 mg orally 2 times a day for 10-14 days total.
Continuation of clindamycin, 450 mg orally, 5 times daily, for 10 to 14 days, may be 
considered as an alternative. Continuation of medication after hospital discharge is 
important for the treatment of possible C. trachomatis infection. Clindamycin has 
more complete anaerobic coverage. Although limited data suggest that clindamy­
cin is effective against C. trachomatis infection, doxycycline remains the treatment 
of choice for patients with chlamydial disease. When C. trachomatis is strongly 
suspected or confirmed as an etiologic agent, doxycycline is the preferable 
alternative. In such instances, doxycycline therapy may be started during hospi­
talization if initiation of therapy before hospital discharge is thought likely to 
improve the patient's compliance.
Rationale
Clinicians have extensive experience with both the cefoxitin/doxycycline and 
clindamycin/aminoglycoside combinations. Each of these regimens provides broad 
coverage against polymicrobial infection. Cefotetan has properties similar to those of 
cefoxitin and requires less frequent dosing. Clinical data are limited on third- 
generation cephalosporins (ceftizoxime, cefotaxime, ceftriaxone), although many 
authorities believe they are effective. Doxycycline administered orally has bioavail­
ability similar to that of the IV formulation and may be given if normal gastrointestinal 
function is present.
*Other cephalosporins such as ceftizoxime, cefotaxime, and ceftriaxone, which provide ade­
quate gonococcal, other facultative gram-negative aerobic, and anaerobic coverage, may be 
utilized in appropriate doses.
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Experimental studies suggest that aminoglycosides may not be optimal treatment 
for gram-negative organisms within abscesses, but clinical studies suggest that they 
are highly effective in the treatment of abscesses when administered in combination 
with clindamycin.
Although short courses of aminoglycosides in healthy young women usually do 
not require serum-level monitoring, many practitioners may elect to monitor levels.
Ambulatory Management of PID
Recommended Regimen
Cefoxitin 2 g IM plus probenecid, 1 g orally concurrently or ceftiaxone 250 mg IM, 
or equivalent cephalosporin
plus
Doxycycline 100 mg orally 2 times a day for 10-14 days
or
Tetracycline 500 mg orally 4 times a day for 10-14 days.
Alternative for Patients Who Do Not Tolerate Doxycycline
Erythromycin, 500 mg orally 4 times a day for 10-14 days may be substituted for 
doxycycline/tetracycline.
This regimen, however, is based on limited clinical data.
Rationale
These empiric regimens provide broad-spectrum coverage against the common 
etiologic agents of PID. Parenteral p-lactam antibiotics are recommended in all cases. 
The cephalosporins are effective in the treatment of gram-negative organisms, 
including enteric rods, anaerobic organisms, and gonococci. Although decreased 
susceptibility of gonococci to cefoxitin has been recently noted, treatment failure has 
not yet been a clinical problem. Patients who do not respond to therapy within 72 
hours should be hospitalized for parenteral therapy. Doxycycline provides definitive 
therapy for chlamydial infections. Patients treated on an ambulatory basis need to be 
monitored closely and reevaluated in 72 hours.
Management of Sex Partners
Sex partners of women with PID should be evaluated for STD. After evaluation, sex 
partners should be empirically treated with regimens effective against N. gonor- 
rhoeae and C. trachomatis infections.
Intrauterine Device (IUD)
The intrauterine device is a risk factor for the development of pelvic inflammatory 
disease. Although the exact effect of removing an IUD on the response of acute 
salpingitis to antimicrobial therapy and on the risk of recurrent salpingitis is unknown, 
removal of the IUD is recommended soon after antimicrobial therapy has been 
initiated. When an IUD is removed, contraceptive counseling is necessary.
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Sexually Transmitted Enteric Infections
Sexually transmitted gastrointestinal syndromes include proctitis, proctocolitis, 
and enteritis. With the exception of rectal gonococcal infection, these syndromes 
occur predominantly in homosexual men who participate in receptive anal inter­
course. Evaluation should include additional diagnostic procedures, such as anos- 
copy or sigmoidoscopy, stool examination, and culture.
Proctitis is inflammation limited to the rectum (the distal 10-12 cm) and is 
associated with anorectal pain, tenesmus, constipation, and discharge. N. gonor- 
rhoeae, C. trachomatis, and HSV are the most common sexually transmitted patho­
gens involved. Among patients coinfected with HIV, herpes proctitis may be espe­
cially severe.
Proctocolitis is associated with symptoms of proctitis plus diarrhea and/or 
abdominal cramps, and the colonic mucosa is inflamed proximal to 12 cm. Etiologic 
organisms include Campylobacter je juni, Shigella spp., amebiasis, and, rarely, 
T. pallidum  or C. trachomatis (often LGV serovars). CMV may be involved in patients 
coinfected with HIV.
Enteritis in homosexual men usually results in diarrhea without signs of proctitis 
or proctocolitis. In otherwise healthy patients, Giardia lamblia is most commonly 
implicated. In patients also coinfected with HIV, CMV. Mycobacterium avium - 
intracellulare, Salmonella spp., Cryptosporidium , and Isospora must be considered. 
Special stool preparations are required to diagnose giardiasis or cryptosporidiosis. 
Additionally, some cases of enteritis may be a primary effect of HIV infection.
All patients with sexually transmitted enteric infections should be counseled and 
tested for HIV infection.
Treatment recommendations for all enteric infections are beyond the scope of 
these guidelines. However, acute proctitis of recent onset in an individual who has 
recently practiced unprotected receptive anal intercourse is most often sexually 
transmitted. Such patients should be examined by anoscopy and should be evaluated 
for infection with N. gonorrhoeae, C. trachomatis, HSV, and T. pallidum. Treatment 
can be based on specific etiologic diagnosis or can be empiric.
Empiric Treatment for Sexually Transmitted Proctitis
Recommended Regimen
Ceftriaxone 250 mg IM plus doxycycline 100 mg orally 2 times a day for 7 days 
provides adequate treatment for gonorrhea and chlamydial infection.
Vaginal Diseases 
Trichomoniasis
Trichomoniasis is almost always a sexually transmitted infection. Diagnosis is 
usually made by direct microscopic visualization (wet preparation) or by culture. 
Diagnosis by cervical cytology or fixed preparation should be confirmed by direct 
visualization or culture. Symptomatic and asymptomatic patients should be treated.
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Recommended Regimen
Metronidazole 2 g orally in a single dose.
Alternative Regimen
Metronidazole 500 mg twice daily for 7 days.
If failure occurs with either regimen, the patient should be retreated with metron­
idazole 500 mg twice daily for 7 days. If repeated failure occurs, the patient should 
be treated with a single 2-g dose of metronidazole daily for 3-5 days.
Cases of additional culture-documented treatment failure in which reinfection has 
been excluded should be managed in consultation with an expert. Evaluation of 
such cases should include determination of the susceptibility of Trichomonas 
vaginalis to metronidazole.
Treatment of Sex Partners
Sex partners should be treated with either the single dose or the 7-day metron­
idazole regimen.
Trichomoniasis During Pregnancy
Metronidazole is contraindicated in the first trimester of pregnancy, and its safety 
in the rest of pregnancy is not established. However, no other adequate therapy 
exists. For patients with severe symptoms after the first trimester, treatment with 2 g 
of metronidazole in a single dose may be considered.
Vulvovaginal Candidiasis
Generally not considered a sexually transmitted disease, vulvovaginal candidiasis 
is frequently diagnosed in women presenting with symptoms involving the genitalia. 
Treatment with antibiotics predisposes women to the development of vulvovaginal 
candidiasis.
Treatment
Many treatment regimens are effective, but 3- and 7-day regimens are superior to 
a single-dose therapy.
Recommended Regimen
Examples of effective regimens include the following:
Miconazole nitrate (vaginal suppository 200 mg), intravaginally at bedtime for 
3 days
or
Clotrimazole (vaginal tablets 200 mg), intravaginally at bedtime for 3 days
or
Butaconazole (2% cream 5 g), intravaginally at bedtime for 3 days
or
Teraconazole 80 mg suppository or 0.4% cream, intravaginally at bedtime for 
3 days.
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hepatitis B (such as homosexual men), prevaccination screening for antibody to 
hepatitis B is cost effective. Prevaccination screening in moderate-risk groups (such 
as heterosexual persons with STD) is usually not indicated.
Hepatitis B Vaccination
Recommendation for Hepatitis B Vaccination
Hepatitis B vaccine (several FDA-approved recombinant or plasma-derived prep­
arations are available) in dosages as recommended by the manufacturer. The 
vaccination series requires an initial visit and two follow-up visits.
Vaccine should not be administered in the gluteal (buttocks) or quadriceps (thigh) 
muscle. After vaccination, testing for antibody response is not routinely indicated 
unless the patient is infected with HIV.
Post-Exposure Prophylaxis
Prophylactic treatment with hepatitis B immune globulin should be considered in 
the following situations: sexual contact with a patient who has active hepatitis B or 
who contracts hepatitis B; sexual contact with a hepatitis B carrier (blood test positive 
for hepatitis B surface antigen). Prophylactic treatment for sexual exposure should be 
given within 14 days of sexual contact. Assay for preexisting immunity to HBV may be 
cost effective if individuals concerned are from populations at high risk for HBV.
Recommendation for Post-Exposure Prophylaxis
Hepatitis B immune globulin (HBIG) .06 ml/kg, IM in a single dose
followed by
Initiation of hepatitis B vaccine series as described above.
Perinatal Infections
Pregnant women with HBV infection can transmit hepatitis B to their infants at 
delivery. Infants infected at birth are at high risk for contracting chronic hepatitis B 
infection. Such infection can be prevented by administering HBIG and hepatitis B 
vaccine to the infant. Therefore, all pregnant women should be screened during their 
first obstetrical visit for the presence of HBsAg. If they are found to be HBsAg-positive, 
their newborns should be given HBIG as soon as possible after birth and subse­
quently should be immunized with hepatitis B vaccine.
Hepatitis guidelines are updated periodically by the Immunization Practices Advi­
sory Committee, and are published in the MMWR. Reference to the most current 
recommendations is advised.
Persons at risk for sexual transmission of hepatitis B are also at risk for HIV and 
other STD. HIV coinfection reduces the humoral response to HB vaccine.
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Cytomegalovirus
Cytomegalovirus (CMV) is a common infection in pregnant women, and 0.5%-2% 
of all infants of CMV-infected women are congenitally infected, although most of 
these infants are only mildly affected. Another 5%-10% of infants are perinatally 
infected; these infections are without known sequelae. The risk of severe congenital 
disease (retardation, deafness, visual problems) is highest when primary CMV 
infection occurs during pregnancy, although recurrent CMV may also cause severe 
congenital infection. Because severe congenital infection occurs before delivery, and 
because CMV infection is widespread, the route of delivery should not be influenced 





Permethrin (1%) creme rinse applied to affected area and washed off after 
10 minutes
or
Pyrethrins and piperonyl butoxide applied to the affected area and washed off 
after 10 minutes
or
Lindane 1% shampoo applied for 4 minutes and then thoroughly washed off. (Not 
recommended for pregnant or lactating women.)
Patients should be reevaluated after 1 week if symptoms persist. Retreatment may 
be necessary if lice are found or eggs are observed at the hair-skin junction.
Sex partners should be treated as above.
Special Considerations. Pediculosis of the eyelashes should be treated by the 
application of occlusive ophthalmic ointment to the eyelid margins, 2 times a day 
for 10 days, to smother lice and nits. Lindane or other drugs should not be applied 
to the eyes. Clothing or bed linen that may have been contaminated by the patient 
within the past 2 days should be washed and/or dried by machine (hot cycle in 
each) or dry cleaned.
Scabies
Recommended Regimen (Adults and Older Children)
Lindane (1%) 1 oz. of lotion or 30 g of cream applied thinly to all areas of the body 
from the neck down and washed off thoroughly after 8 hours. (Not recommended 
for pregnant or lactating women.)
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Alternative Regimen
Crotamiton (10%) applied to the entire body from the neck down for 2 nights and 
washed off thoroughly 24 hours after the second application.
Infants, Children 2 Years O f Age or Less, Pregnant and Lactating Women. For these 
groups, lindane is contraindicated. The crotamiton regimen should be used. 
Contacts. Sex partners and close household contacts should be treated as above. 
Special Considerations. Pruritus may persist for several weeks after adequate 
therapy. A single rereatment after 1 week may be appropriate if no clinical 
improvement occurs. Additional weekly treatments are warranted only if live mites 
can be demonstrated.
Clothing or bed linen that may have been contaminated by the patient within the 
past 2 days should be washed and dried by machine (hot cycle in each) or dry 
cleaned.
Sexual Assault and STD
Recommendations are limited to the identification and treatment of sexually 
transmitted infections. Matters concerning the sensitive management of potential 
pregnancy and of physical and psychological trauma are important and they should 
be addressed, but are beyond the scope of these guidelines. Victims of sexual assault 
are evaluated both to provide necessary medical services and to identify and collect 
forensic evidence. Although some information may be useful for the medical 
management of a victim, this information may not be admissible in court.
Some STD, such as gonorrhea and syphilis, are almost exclusively transmitted 
sexually and may be useful markers of sexual assault. BV is commonly found after 
assault, but is highly prevalent in most populations, which limits its usefulness 
as a marker of assault. Nonculture tests have lower sensitivity and specificity than 
culture techniques.
Sexual Assault
Any sexually transmissible agent, including HIV, may be transmitted during an 
assault. Few data exist on which to establish the risk of an assaulted person's 
acquiring an STD. The risk of acquiring gonococcal and/or chlamydial infections 
appears to be highest. Inferences about STD risk may be based on the known 
prevalences of these diseases in the community. If the suspected assailant is 
identified, that individual should be evaluated for STD to the extent possible under 
the law.
The presence of STD within 24 hours of the assault may represent prior infection 
and not assault-acquired disease. Furthermore, some syndromes, such as BV, may be 
nonsexually transmitted.
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Evaluation
The victim should be initially evaluated for STD within 24 hours of the assault, if 
possible, and evaluation should include the following (see also subsection of 'Test 
Selection and Specimen Handling"):
•  Cultures for N.gonorrhoeae and C. trachomatis from specimens from any sites 
of penetration or attempted penetration
•  Collection of a blood sample for a serologic test for syphilis and for storage of a 
serum sample for possible future testing. Serologic testing for HIV and hepatitis 
B infection should be considered
•  For women, examination of vaginal specimens for T. vaginalis and for evidence 
of BV
•  Pregnancy test
Follow-up evaluations should be scheduled after 14-21 days, to repeat studies 
other than those for syphilis and viral STD. A third visit may be scheduled at 
8-12 weeks to repeat initial serologic studies, including tests for antibodies to syphilis 
and/or hepatitis B, and/or HIV.
Treatment
Treatment should be given for any infection identified on examination or for any 
infection identified in the assailant. Although the risk of infection is frequently low, 
use of presumptive treatment is controversial. Some experts recommend presump­
tive treatment for all victims of sexual assault, whereas some reserve presumptive 
treatment for special circumstances, for example, when follow-up examination of the 
victim cannot be ensured or when treatment is specifically requested by the patient. 
Although no regimen covers all potential pathogens, the following regimens should 
be effective against gonorrhea, chlamydia, and, most likely, syphilis.
Empiric Regimen for Victims of Sexual Assault
Ceftriaxone, 250 mg, given IM,
to be followed by either
Doxycycline 100 mg orally 2 times a day for 7 days
or
Tetracycline HCI 500 mg orally 4 times a day for 7 days.
Sexual Assault and Abuse of Children
The identification of a sexually transmissible agent from a child beyond the 
neonatal period suggests sexual abuse. However, exceptions do exist, e.g., rectal and 
genital infection with C. trachomatis in young children may be due to persistent 
perinatally acquired infection, which may persist for up to 3 years. In addition, BV and 
genital mycoplasmas have been identified in both abused and nonabused children.
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A finding of genital warts, although suggestive of assault, is nonspecific without other 
evidence of sexual abuse. When the only evidence of sexual abuse is the isolation of 
an organism or the detection of antibodies, findings should be carefully confirmed.
Evaluation
Among sexually abused children, the prevalence of STD appears relatively low; in 
most studies, C. trachomatis is the most frequently isolated organism. Sexually 
abused children are best managed by a team of professionals experienced in dealing 
with the many needs of children. Although testing for the diseases appropriate for 
children (Table 5) is essentially the same as that for adults, the special needs of 
children must be taken into account.
Recommended evaluation of suspected child abuse/assault
•  Since a child's report of assault may not be complete, specimens for culture for 
N. gonorrhoeae and C. trachomatis should be collected from the pharynx and 
rectum as well as from the vagina (girls) or urethra (boys).
•  Internal pelvic examinations usually should not be performed unless indicated 
by the presence of a foreign body or by trauma.
•  Follow-up visits should be scheduled so as to minimize trauma to the child; for 
asymptomatic children, an initial visit and one visit at 8-12 weeks may be 
sufficient.
•  In cases of continuing abuse, the alleged offender may be available for medical 
evaluation. In such instances, care for the child may be modified when results of 
the evaluation of the offender are known.
Treatment
Treatment before diagnosis is not indicated unless evidence shows that the 
assailant is infected. Presumptive treatment after assault may be given if the victim or 
victim's family requests it or if follow-up examination of the victim cannot be ensured.
TABLE 5. Recommended laboratory procedures at initial and follow-up evaluation of 
sexually abused children (prepubertal)
Gram stain of any genital or anal discharge*
Culture for Neisseria gonorrhoeaer
Culture for Chlamydia trachomatisx
Wet preparation of vaginal secretion for trichomonads
Culture of lesions for herpes simplex virus (HSV)
Serologic test for syphilis
Serologic test for human immunodeficiency virus (HIV)* 5 
Frozen serum sample
Note. Syphilis and HIV serology should be repeated in 12 weeks. All other tests 
should be repeated 10-14 days after the initial examination.
♦Care should be taken in the interpretation of results of any Gram stain of any anal discharge. 
Cultures of pharynx, rectum, and vagina/urethra should be done.
5 Testing for HIV should be based on the prevalence of infection and on suspected risk.
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Test Selection and Specimen Handling
When a sexually transmitted agent is identified from a sexually abused adult or 
child, the positive laboratory report may be required in pending legal action. Isolation 
of gonorrhea and chlamydia organisms by culture, and their confirmation by 
recognized techniques, is standard. All presumptive isolates of N. gonorrhoeae from 
children should be confirmed by at least two tests that involve different principles, 
e.g., biochemical, enzyme substrate, or serologic. Direct specimen antigen-detection 
tests or DNA probe tests are not recommended for use on specimens from any 
victim of sexual abuse. These tests may be used to diagnose C. trachomatis in adults 
only in areas where culture is not available. Results of nonculture tests may be used 
to guide medical management but should not be used for forensic purposes. The 
potential for an inaccurate result is greatest in children, and nonculture tests are not 
recommended in the evaluation of sexual assault or sexual abuse in children. Isolates 
should be stored at -70 C for possible future studies, and the use of a reference 
laboratory should be considered. Expert laboratory consultations are recommended 
for testing as well as for chain-of-evidence issues. *
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